

HHS Public Access

Author manuscript *Nat Immunol.* Author manuscript; available in PMC 2022 December 07.

Published in final edited form as:

Nat Immunol. 2022 July ; 23(7): 1052-1062. doi:10.1038/s41590-022-01232-z.

TCF-1 promotes chromatin interactions across topologically associating domains in T cell progenitors

Wenliang Wang^{1,2,3,4,*}, Aditi Chandra^{1,2,3,4,*}, Naomi Goldman^{1,2,3,4,*}, Sora Yoon^{1,2,3,4,*}, Emily K. Ferrari^{1,2,3,4,*}, Son. C. Nguyen^{1,3}, Eric F. Joyce^{1,3}, Golnaz Vahedi^{1,2,3,4,5,#}

¹Department of Genetics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA

²Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA

³Epigenetics Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA

⁴Institute for Diabetes, Obesity and Metabolism, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA

⁵Abramson Family Cancer Research Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA

Abstract

The high mobility group (HMG) transcription factor TCF-1 is essential for early T cell development. Although *in vitro* biochemical assays suggest that HMG proteins can serve as architectural elements in the assembly of higher-order nuclear organization, the contribution of TCF-1 on the control of three-dimensional (3D) genome structures during T cell development remains unknown. Here, we investigated the role of TCF-1 in 3D genome reconfiguration. Using gain and loss of function experiments, we discovered that the co-occupancy of TCF-1 and the architectural protein CTCF altered the structure of topologically associating domains in T cell progenitors, leading to interactions between previously insulated regulatory elements and target genes at late stages of T cell development. The TCF-1 dependent gain in long-range interactions was linked to deposition of active enhancer mark H3K27ac and recruitment of the cohesin-loading

Competing Interests Statement

The authors declare no competing interests.

Code availability

[#]Corresponding author: vahedi@pennmedicine.upenn.edu, 421 Curie Blvd, Room 314, Philadelphia, PA 19104-6160, Phone: Office (215) 898-8439.

These authors contributed equally

Author Contributions Statement

A.C. performed all genomics and sequencing experiments in collaboration with N.G.. N.G. generated the $Tcf7^{-/-}$ mice. A.C. performed computational analysis of ChIP-seq data in DN3. W.W. performed all computational analysis of genomics data in the first submission and wrote the initial draft of the first submission. S.Y. performed all computational analysis for genomics and imaging data for two revisions. E.K.F. performed all FISH experiments and assisted in mouse breeding. S.C.N and E.F.J. assisted in Oligopaint probe design. G.V. conceptualized and supervised the project, wrote the manuscript, revised it with comments from all authors and acquired funding.

The codes for Stripenn and data analysis are available from the author's Github page (https://github.com/VahediLab/TCF13D_code).

factor NIPBL at active enhancers. These data indicate that TCF-1 has a role in controlling the global genome organization during T cell development.

The mammalian genome is folded into higher-order 3D structures with globular interaction domains¹. These structures, variously called topologically associating domains (TADs) or insulated neighborhoods^{2–6}, sequester regulatory elements, insulating them from genomic regions outside such domains. The ubiquitously-expressed protein CTCF has a prominent role in creating insulated neighborhoods through its convergent binding events, which can block cohesin-mediated loop extrusion^{7,8}. A small number of lineage-determining transcription factors (LDTFs) which can endow competence to new developmental programs have been shown to control 3D genome structure^{8–12} but the underlying mechanisms of this control are not fully understood.

The T cell developmental pathway represents a leading exemplar to understand global genome organization¹³. T cell development starts when bone marrow-derived precursors seed the thymus and give rise to early thymic progenitors (ETP)¹⁴. TCF-1, encoded by *Tcf7*, is upregulated at ETP by Notch1 and remains highly expressed until maturation. This protein can control the expression of Gata3 and Bcl11b, which are necessary for T lineage commitment^{15,16}. TCF-1 can also bind to nucleosomal DNA and create novel accessible regulatory elements^{17,18}. Biochemical studies have indicated that the HMG proteins like TCF-1 and LEF1 can bend DNA^{19,20}. Moreover, TCF-1 is linked to 3D genome organization of peripheral CD8⁺ T cells²¹ and T leukemic cells^{22,23}. Yet, the role of TCF-1 on genome folding during T cell development is unknown.

Here we assessed whether the early and continuous expression of TCF-1 in the thymus had a role in chromatin folding. Employing gain and loss of function experiments, we observed that TCF-1 targeted boundaries of insulated neighborhoods in T cell progenitors, weakened the insulation between adjacent neighborhoods, and enhanced long-range interactions between regulatory elements and target genes located on previously insulated domains. TCF-1-dependent long-range interactions were linked to the recruitment of the cohesinloading factor NIPBL to active enhancers. Our finding of TCF-1-dependent chromatin interactions across insulated neighborhoods demonstrates an LDTF dismantling insulation during a developmental trajectory.

Results

TCF-1 occupancy correlates with intra-TAD interactions

To study the relationship between TCF-1 occupancy and 3D genome folding during T cell development, we employed publicly available ChIP-seq measurements of TCF-1 binding events in thymocytes²⁴ and Hi-C measurements of 3D genome interactions at different T cell developmental stages, including pre-commitment (CLP, ETP, and DN2) and post-commitment (DN3, DN4, and DP) stages²⁵. We defined TADs in DPs using the insulation score strategy²⁶, grouped TADs based on TCF-1 binding density and evaluated the extent of intra-TAD interactions. The increase in intra-TAD interactions in DPs compared with ETPs-DN4s was significantly correlated with the density of TCF-1 binding events within

TADs (Fig. 1a), suggesting that genomic domains with the strongest TCF-1 occupancy acquired the largest extent of *de novo* 3D interactions in DPs.

To explore the association between TCF-1 binding and finer scale 3D structures, we identified cohesin-associated loops using SMC1 HiChIP in DPs²⁷. Of the 149,315 loops detected in DPs, more than 40% were occupied by TCF-1 at least on one anchor, which was comparable to CTCF binding pattern (Fig. 1b) while 32% of loops were co-bound by TCF-1 and CTCF (Fig. 1b). To evaluate the genome-wide co-occupancy of these two proteins, we grouped CTCF and TCF-1 binding events in DPs into CTCF alone, TCF-1 alone, and regions co-occupied by both proteins (Fig. 1c, Supplementary Table 1). CTCF and TCF-1 co-occupancy accounted for ~20% of TCF-1 bound regions (Fig. 1c). The HMG motif was enriched at CTCF and TCF-1 co-bound sites (Fig. 1d), implying the direct binding of TCF-1 protein at these loci. The occupancy of CTCF and TCF-1 was associated with dense cohesin loops at the *Cd8a* (Fig. 1e), *Ets1* (Extended Data Fig. 1a) and *Tcf7* (Extended Data Fig. 1b) loci.

We next assessed the extent of long-range interactions between the regulatory elements in each TCF-1 binding group and genes that are selectively regulated during T cell development using single-cell RNA-seq profiling of thymocytes²⁸ (Supplementary Table 2) and found that TCF-1 and CTCF co-bound sites had the strongest interactions with stage-specific genes (Fig. 1f). Thus, TCF-1 and CTCF co-occupancy might be a structurally salient feature of T cell development.

TCF-1 and CTCF co-binding weakens insulation at boundaries

We next measured the average 3D interactions anchored at the CTCF, TCF-1 or TCF-1+CTCF peaks, and a set of randomly sampled regions that lacked either protein as control. In CLPs, ETPs, and DN2s, TCF-1+CTCF sites had limited interactions between their upstream and downstream regions (Fig. 2a). The insulation at TCF-1+CTCF sites was gradually lost starting in DN3s (Fig. 2a), suggesting interactions between upstream and downstream insulated domains centered at TCF-1+CTCF sites. The interactions between the two sides of TCF-1-only regions also started to increase in DN3s (Fig. 2a), while the CTCFoccupied sites remained insulated throughout T cell development (Fig. 2a). To quantitatively assess changes in insulation at TCF-1+CTCF sites, we calculated genome-wide insulation scores²⁶. We found that insulation at TCF-1+CTCF sites, but not CTCF-only sites, gradually declined during T cell development starting from DN3s (Fig. 2b and Extended Data Fig. 2a). The increase in insulation score in DPs compared to CLPs was significantly larger at TCF-1+CTCF sites compared with TCF-1 or CTCF regions (Extended Data Fig. 2b), indicating that co-binding of TCF-1 and CTCF could increase interactions across insulated neighborhoods, leading to a loss of insulation as T cells become more mature. Co-bound sites were preferentially enriched closer to genes expressed at DN3 and DN4 stages²⁸ compared to genes associated with other stages (Fig. 2c, Supplementary Table 3). Thus, insulation at TCF-1+CTCF sites declined post T cell commitment due to de novo long-range interactions at T cell commitment genes.

Based on the quantitative definition of TAD boundaries, the number of boundaries steadily decreased from ETP to DP (Extended Data Fig. 2c), suggesting the reorganization of

TADs during T cell development. We further classified the boundaries into different groups according to their quantitative detection at each stage. We detected boundaries with mixed patterns of gain or loss (group I), boundaries that remained invariant during development (group H), boundaries that formed after T cell commitment (groups A and B), and boundaries that were lost at different stages (groups C, D, E, F and G) (Extended Data Fig. 2d, Supplementary Table 4). Examination of the long-range contacts across the nine groups indicated increased across boundary interactions at DN3s-DPs compared with CLPs to DN3s at lost boundaries and fewer across boundary interactions in DN3s to DPs at gained boundaries (Extended Data Fig. 2e,f). The interactions across domains separated by dynamic boundaries were confirmed by insulation score and directionality index analyses (Extended Data Fig. 3a,b). The percentage of group C boundaries that were in compartment B (PC1 <0) increased markedly between CLPs and DPs (Extended Data Fig. 3c). Lost boundaries in groups E and F were largely in compartment A in both CLPs and DPs (Extended Data Fig. 3c,d), suggesting no compartmental switching as thymocytes matured.

Next, we calculated the average occurrence of peaks for each binding group within 500 kb of dynamic boundaries. While CTCF-only sites were enriched at most boundaries (Extended Data Fig. 3e–h), TCF-1+CTCF as well as TCF-1-only sites were enriched at lost boundaries in groups E and F (Extended Data Fig. 3f–i). Analysis of histone acetylation and chromatin accessibility²⁹ indicated that boundaries lost at DN3s and DN4s (group E and F) were highly associated with active enhancer marks, as well as transcriptionally active and accessible chromatin states across T cell development (Extended Data Fig. 3h,i), suggesting that TCF-1 binding events, especially TCF-1+CTCF regions, were abundant in transcriptionally active and open chromatin domains.

We found multiple boundaries in the *Cd3d-g* and *Cd8a-b* loci in CLPs and ETPs that weakened in DPs (Fig. 2d,e), suggesting that boundary weakening between two adjacent domains at loci encompassing T cell development genes corresponded to novel interactions between previously insulated domains. Dense TCF-1 occupancy was accompanied by increased expression of the *Cd3d-g* and *Cd8a-b* genes in DN3s-DPs (Fig. 2d,e). A cluster of TCF-1 binding events at a boundary encompassing the *Cd3* locus corresponded to loss of insulation and gain in long-range interactions across the boundary at DN3s to DPs (Fig. 2d). Moreover, multiple TCF-1 binding events that occurred near the boundary of *Cd8a-b* locus, were also associated with loss of insulation and extensive long-range interactions (Fig. 2e). New boundaries were also detected at select loci such as a cluster of TCF-1 binding events at the *Rag1-Rag2* locus (Extended Data Fig. 3j), corresponding to increased expression of these genes in mature T cells. Thus, TCF-1+CTCF co-binding was associated with dynamic domain boundaries encompassing T cell identity genes.

TCF-1+CTCF sites are evolutionarily conserved

We next examined the conservation scores of DNA sequences centered on different classes of CTCF and TCF-1 binding events. We found a sharp increase in sequence conservation at genomic regions with CTCF only or TCF-1 only peaks and an even broader and stronger degree of sequence conservation at TCF-1+CTCF sites (Extended Data Fig. 4a). To further explore the insulation status of conserved binding sites in human T cells, we

employed Hi-C data from T cell acute lymphoblastic leukemia (T-ALL) and ETP leukemia (ETP-ALL)³⁰, which arise from malignant transformation of T cell precursors. Moreover, we generated Hi-C maps from mature lymph node CD8⁺ T cells from one healthy organ donor (Extended Data Fig. 4b). We evaluated the extent of insulation and long-range 3D interactions at homologous CTCF and TCF-1 binding sites in the human genome and found loss of insulation at TCF-1+CTCF sites in mature CD8⁺ T cells compared to T-ALLs and ETP-ALLs (Extended Data Fig. 4b). We further analyzed the average local interactions at TCF-1+CTCF sites in multiple mouse cell types (Extended Data Fig. 4c). While the CTCF sites appeared insulated in all examined cell types, TCF-1 sites showed increased interactions only in naïve CD4⁺ T cells and DPs (Extended Data Fig. 4c). Based on analysis of public Hi-C data from 4D Nucleome project³¹, the TCF-1+CTCF sites exhibited the same level of insulation as CTCF sites in all non-T cell lines examined (Extended Data Fig. 4d). Thus, the highly conserved TCF-1+CTCF sites were insulated in non-T cells and early T cell progenitors in both humans and mice.

Overexpression of TCF-1 in fibroblasts creates de novo 3D interactions

To ask whether TCF-1 expression was required for long-range interactions across co-bound TCF-1+CTCF boundaries, we used fibroblasts because T cell lineage collaborators of TCF-1 are not expressed in this cell type. We overexpressed TCF-1 in the fibroblast cell line NIH-3T3 using lentiviral transduction with a doxycycline-inducible gene expression system (hereafter 3T3^{TCF-1}). We measured TCF-1 and CTCF binding events and transcriptional outputs before and 72h post-TCF-1 induction by doxycycline in biological replicates (Supplementary Fig. 1), using ChIP-seq and RNA-seq, respectively. Transcriptomic measurements indicated the increased expression of 273 genes and decreased expression of 194 genes in 3T3^{TCF-1} compared to non-induced fibroblasts (Extended Data Fig. 5a, Supplementary Table 5). 1,872 CTCF binding events were predominantly stronger and 431 CTCF binding events were weaker in 3T3^{TCF-1} fibroblasts (Extended Data Fig. 5b). Thus, TCF-1 expression can interfere with the transcriptional control of fibroblasts¹⁷.

Next, we measured cohesin-mediated 3D genome interactions using SMC1 HiChIP before and after TCF-1 induction. Only a small number of regions switched compartments between 3T3^{TCF-1} and non-induced fibroblasts (Extended Data Fig. 5c). The overall compartmentalization, measured by the compartment strength (Extended Data Fig. 5d) or the extent of BB, AA and AB interactions (Extended Data Fig. 5e), was similar in 3T3^{TCF1} and non-induced fibroblasts, suggesting that TCF-1 expression did not alter the compartmentalization of the fibroblast genome 72h post induction. Most TAD boundaries were conserved (Extended Data Fig. 5f,g); however, we observed a significant increase in intra-TAD interactions within invariant TADs in 3T3^{TCF-1} compared to non-induced fibrobalsts (Fig. 3a). Measurements of the connectivity within a TAD, referred to as "domain score"³², indicated significantly larger domain scores in 3T3^{TCF-1} compared with non-induced fibroblasts (Fig. 3b), suggesting that TCF-1 can promote intra-TAD interactions. The density of TCF-1 binding correlated significantly with changes in domain score after TCF-1 induction (Extended Data Fig. 5h), suggesting that dense TCF-1 binding corresponded to a substantial increase in intra-TAD interactions. TCF-1+CTCF sites had the largest increase in 3D interactions in 3T3^{TCF-1} (Fig. 3c), suggesting their cooperativity

in mediating 3D interactions. The increase in interactions originating from each genomic region was positively correlated with the number of TCF-1 peaks in the neighborhood (Extended Data Fig. 5i,j). The greatest increase in 3D interactions occurred when TCF-1 occupied both anchors and had high density at neighboring regions (Extended Data Fig. 6k,l). Thus, as exemplified at the *Irt2bp2* locus (Fig. 3d), TCF-1 could increase intra-TAD interactions in fibroblasts at many loci.

TCF-1 controls the 3D chromatin conformation of T cells

T cells undergo a remarkable genome reorganization during the DN2-to-DN3 transition²⁵. To explore whether TCF-1 was required for the 3D genome organization during T cell development, we genetically ablated TCF-1 expression using CRISPR/Cas9 (Extended Data Fig. 6a) in a DN3-like T cell line, also called *Scid.adh*³³. In addition, we generated Vav-Cre Tcf7fl/fl mice, in which TCF-1 is conditionally ablated in all hematopoietic cells (Extended Data Fig. 6b), as indicated by immunoblot experiments (Extended Data Fig. 6c) and flow cytometry in the thymus (Extended Data Fig. 6d). We next mapped the global chromatin conformation using ultra-deep Hi-C measurements in DN3 cell lines and primary DPs in wildtype and TCF-1 deficient T cells (hereafter $Tcf7^{-/-}$ DN3s and DPs). We detected overall modest changes of PC1 values between wild-type and Tcf7^{-/-} cells (Extended Data Fig. 6e,f). However, we observed weakening of compartment strengths in $Tcf7^{-/-}$ DPs (Figs. 3e). There was also a significant decrease of interactions in A compartment in both *Tcf7*^{-/-} DN3s and DPs, a significant decrease in compartment strength in Tcf7^{-/-} DPs, and a significant increase of interactions between A and B compartments in *Tcf7*^{-/-} DPs (Fig. 3f and Extended Data Fig. 6h) compared to their wild-type counterparts. These data suggest TCF-1 was required for the establishment and maintenance of long-range interactions at the compartment level in DN3s and DPs. Most TAD boundaries were conserved between wild-type and $Tcf7^{-/-}$ cells (Extended Data Fig. 6i,j), but there was a significant reduction in intra-TAD interactions and hence, reduced domain scores in $Tcf7^{-/-}$ cells compared with wild-type DN3s and DPs (Fig. 3g), positing that TCF-1 was required for the increase in de novo 3D interactions at these stages.

In *Tcf7*^{-/-} DN3s (or *Tcf7*^{-/-} DPs), 196 (or 525) genes were downregulated, while 374 (or 664) genes were upregulated (Supplementary Tables 6–9). To ascertain whether TCF-1-dependent changes in intra-TAD interactions related to changes in transcriptional outputs, we investigated the expression of genes located in the top 50 TADs, which had the greatest change in their domain scores in *Tcf7*^{-/-} cells. Genes positioned in TADs whose domain scores increased in *Tcf7*^{-/-} DN3s and DPs were upregulated in *Tcf7*^{-/-} DN3s and DPs (Extended Data Fig. 6k,l, Supplementary Table 10), while genes whose domain scores decreased after TCF-1 deletion were downregulated in *Tcf7*^{-/-} DN3s and DPs (Extended Data Fig. 6k,l, Supplementary Table 10). Gene-ontology analysis indicated that genes positioned in TADs whose domain scores decreased in *Tcf7*^{-/-} DPs were enriched in ontologies including 'lymphocyte activation', 'cytokine signaling in immune system' and 'IL-2 signaling' (Fig. 3h,i and Supplementary Table 11), while genes whose domain scores decreased in *Tcf7*^{-/-} DN3 were enriched in 'cellular response to IFN-beta' (Extended Data Fig. 6m, Supplementary Table 11), indicating a potential regulatory role of TCF-1 on IFN-induced genes by directly reorganizing 3D genome folding. These findings indicated the

requirement of TCF-1 for intra-TAD interactions, which are necessary for the transcriptional control of genes with developmental roles in T cells.

A dense cluster of TCF-1 binding events on IFN-induced genes corresponded to TCF-1 dependent SMC1 occupancy and 3D interactions (Extended Data Fig. 7a), suggesting the potential role of TCF-1 protein in recruiting the cohesin subunit. To further investigate whether sequence variation at this TCF-1 binding cluster can alter the 3D genome interactions and thus the expression of IFN-induced genes within this domain, we utilized the SMC1 HiChIP data in DPs in C57BL/6 and NOD²⁷, which showed differences in the intra-TAD interactions (Extended Data Fig. 7b). A cluster of TCF-1 binding events coincided with stronger interactions in NOD compared with C57BL/6 DPs (Extended Data Fig. 7b). Consequently, most genes had higher expression in NOD compared with C57BL/6 DPs (Extended Data Fig. 7c). Long-range interactions at this domain were also TCF-1 dependent in fibroblasts and DPs (Extended Data Fig. 7d,e). Thus, TCF-1 was required to maintain long-range interactions at various length scales.

TCF-1 is required to diminish insulation

To investigate the extent to which TCF-1 acted on insulated neighborhoods, we examined interactions at TCF-1+CTCF sites in 3T3^{TCF-1} fibroblasts in addition to *Tcf7^{-/-}* DN3s and DPs. We first quantified the interactions at a 500kbp region centered around different classes of TCF-1 and CTCF binding events in 3T3^{TCF-1} fibroblasts. Among 12,143 TCF-1+CTCF sites, interactions between upstream and downstream domains centered at 2,435 co-bound sites increased in 3T3^{TCF-1} fibroblasts compared with non-induced fibroblasts (Fig. 4a, Supplementary Table 12). Among 27,353 TCF-1 peaks, the interaction and insulation changed at 6,868 sites (Fig. 4a,b).

To test whether TCF-1 was required to reshape the insulated neighborhoods, we quantified 3D interactions in wildtype, $Tcf7^{-/-}$ DN3s and DPs using our ultra-deep Hi-C measurements. We mapped TCF-1 binding events in DN3s using TCF-1 ChIP-seq and compared TCF-1 occupancy in DN3s with the genome-wide profile based on the public TCF-1 ChIP-seq data in thymocytes²⁴ (Extended Data Fig. 8a). Based on the number of peaks, the public TCF-1 ChIP-seq data in thymocytes was of higher quality (Extended Data Fig. 8a), so we employed them in analyses of DN3s and DPs. Loss of TCF-1 in DN3s led to reduced interactions at 988 TCF-1+CTCF sites (Fig. 4c,d, Supplementary Table 13) and 5,439 TCF-1-only sites (Fig. 4c,d), with a corresponding increase in insulation. These effects were reproduced in another *Tcf7*^{-/-} DN3 clone (Extended Data Fig. 8b). The effect of TCF-1 deletion in DPs on long-range interactions centered at TCF-1+CTCF sites was even more prominent than that in DN3s, and led to reduced interactions at 3,707 TCF-1 and CTCF co-bound peaks, while 15,151 TCF-1-only sites showed loss of 3D interactions (Fig. 4e.f. Supplementary Table 14). Hi-C data from wild-type and Bcl11b-deficient naïve CD4⁺ T cells²⁵ indicated no effect of Bcl11b on insulation (Extended Data Fig. 8c). As representative examples, the Rtkn (Fig. 4g), II33 (Fig. 4h) and II17d (Fig. 4i) loci showed statistically significant changes in chromatin interactions between 3T3^{TCF-1} and non-induced 3T3 in addition to wildtype and *Tcf7*^{-/-} DN3s and DPs. Thus, TCF-1 binding could change local interactions between insulated domains.

Oligopaint 3D FISH corroborates genomic measurements

A robust identification of TADs is still lacking due to the relatively low concordance of TAD definitions^{34,35}. We used alternative methodologies to quantify interaction frequencies across TCF-1 dependent boundaries. We tested how chromatin interactions measured by Hi-C related to spatial localization of adjacent TADs using high-resolution Oligopaint DNA fluorescence *in situ* hybridization (FISH) with confocal imaging in $3D^{36,37}$. Because we detected TCF-1-dependent chromatin interactions across domains at the Cd8a-Cd8b1 locus in fibroblasts, DN3s and DPs (Fig. 5a and Extended Data Fig. 9a,b) we tiled Oligopaint probes along two domains of this locus, referred to as TAD1 (~284 kbp) and TAD2 (~437 kbp) (Fig. 5a), which were insulated in ETP-DN2 and combined into one domain after DN3. Because the largest extent of interactions across boundaries was detected at DPs, we performed Oligopaint FISH experiments in wild-type and $Tcf7^{-/-}$ DPs. To assess the spatial proximity of TADs, we measured the distance between centroids of each domain across individual alleles and used a 3D segmentation strategy³⁸ to trace the edges of each domain's signal, generating a distribution of domain volumes across ~300 alleles per condition (Fig. 5b). To report the fraction of overlap between two domains across single alleles, the overlap volume of TAD1 and TAD2 per allele was normalized to the volume of TAD1. If chromatin interactions across boundaries at the Cd8a-Cd8b1 locus in DPs was TCF-1-dependent, that would be reflected in a reduction in overlap between TAD1 and TAD2 volumes and an increase in distance between TAD1 and TAD2 centroids in $Tcf7^{-/-}$ compared with wildtype DPs. Representative examples of alleles at the *Cd8* locus in wildtype and *Tcf7*^{-/-} DPs and 3D rendering of TAD1 and TAD2 at the single-cell level corroborated the TCF-1-dependent spatial localization of two adjacent TADs (Fig. 5b,c). This finding was also confirmed for hundreds of DPs across biological replicates (Fig. 5d,e and Extended Data Fig. 9c,d). As such, high-resolution imaging quantified the TCF-1-dependent chromatin interactions across boundaries, independent of sequencing techniques at the single-allele level.

TCF-1 recruits NIPBL to reconstruct 3D genome

TADs are formed by cohesin-mediated extrusion of DNA¹. Subunits of the cohesin complex are loaded onto chromatin by NIPBL and MAU2³⁹⁻⁴¹ and once loaded, they extrude DNA until convergent CTCF sites are recognized^{42–45}. Although TCF-1 overexpression in fibroblasts or TCF-1 deletion in DN3s changed CTCF occupancy (Extended Data Figs. 5b and 10a), CTCF binding at TCF-1-dependent boundaries remained unchanged (Extended Data Fig. 7). We mapped the genome-wide binding patterns of NIPBL and SMC1 and measured the chromatin signature of active enhancers using H3K27ac ChIP-seq in wild-type and $Tcf7^{-/-}$ DN3s in biological replicates (Supplementary Figs. 2–3). We created a binding atlas of cohesin occupancy in DN3s by combining SMC1 and NIPBL peaks across various conditions and evaluated genomic regions with gain or loss of SMC1 and NIPBL, in addition to deposition of H3K27ac after TCF-1 deletion in DN3s. H3K27ac was lost in Tcf7^{-/-} DN3s at more than 2,000 genomic regions, concomitant with an evident diminution of NIPBL and SMC1 binding at these sites (Fig. 6a, Supplementary Table 15). Notably, the overt chromatin accessibility at these regions, as measured by ATAC-seq, did not change commensurately (Fig. 6a). As a representative example, H3K27ac, SMC1 and NIPBL binding events were concordantly reduced in *Tcf7*^{-/-} DN3s at a cluster of interferon-induced transmembrane genes (Fig. 6b). Gain of H3K27ac and co-occupancy of NIPBL and SMC1

occurred at more than 1,300 genomic regions in $Tcf7^{-/-}$ DN3s (Fig. 6c,d, Supplementary Table 16). ETS, RUNX, and TCF recognition motifs were enriched at sites where cohesin complex occupancy was lost in $Tcf7^{-/-}$ DN3s (Fig. 6e), while CTCF-like recognition motifs were enriched at genomic regions that gained cohesin occupancy in $Tcf7^{-/-}$ DN3s (Fig. 6f) compared to wild-type DN3s. SMC1 ChIP-seq indicated a similar motif enrichment lost in $Tcf7^{-/-}$ DN3s (Extended Data Fig. 10c, Supplementary Table 8). The long-range interactions anchored at TCF-1-dependent SMC1+NIPBL co-occupied regions that carried the H3K27ac signature were also TCF-1-dependent (Fig. 6g,h). Moreover, the TCF-1dependent SMC1+NIPBL co-bound enhancers were enriched near weakened boundaries bound by TCF-1+CTCF (Extended Data Fig. 10d). Together, TCF-1 established the active enhancer repertoire and sequestered the cohesin machinery to these enhancers, a process which can create *de novo* long-range interactions and cause weakening of the previously insulated neighborhoods.

Discussion

Here, we showed that co-binding of TCF-1 and CTCF earmarked TAD boundaries which reorganized during T cell development. The disruption of TAD boundaries, such as domains encompassing the *Cd8* and *Cd3* clusters, was accompanied by interactions of regulatory elements previously located in different insulated neighborhoods. Key regulatory elements and their target genes were spatially distanced on different TADs during early developmental stages when these target genes were transcriptionally silent. Our data indicated that TCF-1 endowed competence to the T cell developmental program by minimizing the spatial distance between regulatory elements required for the proper expression of T cell genes, even when located within insulated neighborhoods in progenitors.

The ability of TCF-1 to recruit NIPBL and the cohesin complex at active enhancers implied a possible mechanism through which TCF-1 could diminish insulation at TAD boundaries. Degrading the histone acetyltransferases P300 leads to loss of NIPBL loading, suggesting histone acetylation may represent a signal for cohesin loading⁴⁶. We speculate that TCF-1-mediated histone acetylatation can lead to accumulation of NIPBL and recruitment of the cohesin complex, which in turn would lead to chromatin interactions across TCF-1 bound loci. Considering that TCF-1 expression is induced at ETP, it is puzzling why it takes so long for the boundary dynamics to occur after DN3s. We speculate that the cohesin-complex-mediated genome reorganization during T cell development might be rate limiting. This hypothesis is supported by the increased expression of NIBPL at DPs (ImmGen data), but further experiments are required. Whether the HMG domain of TCF-1 bends DNA to assist the cohesin complex during genome reorganization remains to be shown.

Although our work established an effect of TCF-1 on genome folding, it remains unclear to which extent the TCF-1-dependent global genome organization relates to transcriptional control. The emerging view is that transcription factors can alter genome organization prior to mediating transcriptional control. Pre-existing loops and the requirement of stage-specific histone acetylation for gene expression has been reported^{47,48}. It is enticing to speculate that TCF-1 sets the thymocytes 3D genome landscape up for transcriptional control once T cells specialize and expand in the periphery. Additional work is needed to elucidate if

CTCF and TCF-1 co-binding events enable spatial contacts between regulatory elements of genes essential in stem-like or memory CD8⁺ T cells. Despite these new questions, our study describes an LDTF with the ability to eliminate TAD-enforced spatial distance between regulatory elements and their target genes in progenitors. We speculate that other LDTFs might be proficient to enable interactions between regulatory elements and target genes in other developmental pathways.

METHODS

Resource availability

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Golnaz Vahedi (vahedi@pennmedicine.upenn.edu).

Materials availability

This study did not generate new unique reagents.

Cell culture

NIH 3T3 cells were purchased from ATCC as described ¹⁷ and maintained at a low passage number (< 12) using high glucose 1× DMEM medium with L-glutamine (GIBCO) with 100 U mL-1 penicillin and 100 mg mL-1 streptomycin (GIBCO) and 10% bovine serum (GIBCO). 293T (ATCC) cells were maintained in high glucose DMEM 1× medium with L-glutamine (GIBCO), and 100 U mL-1 penicillin and 100 mg mL-1 streptomycin (GIBCO) with 10% fetal bovine serum (FisherScientific). Scid.adh cell line, a pro-T cell line derived from spontaneous thymic lymphomas ⁶⁴, was a kind gift from Warren Pear's lab at the University of Pennsylvania. These cells were grown in RPMI 1640 medium (Invitrogen), supplemented with 10% fetal bovine serum (FisherScientific), 1mM sodium pyruvate (Gibco), 1% non-essential amino acids (Gibco), 2 mM L-Glutamine (Lonza), 1% penicillin-streptomycin and 0.1% 2-Mercaptoethanol (Gibco). All cells were grown at 37°C and 5% CO2.

Mice

Female and Male breeder Vav-iCre transgenic mice (Strain #008610)^{65–67} and Tcf7^{eGFP} Mice (strain # 030909)⁶⁸ were purchased from Jackson Laboratory. "Tcf7–/–" mice were generated by breeding Tcf7^{eGFP} mice, in which 2 *loxP* sites are inserted on either side of exon 2 of the *Tcf7* gene, with Vav-iCre mice. The F1 generation was backcrossed to Tcf7^{eGFP} mice to reach homozygous floxed Cre+ experimental mice. Vav-iCre+ control mice were generated by crossing Vav-iCre mice with C57BL6/J (strain # #000664) and used as controls in all experiments. Experimental and control mice were 6–10 weeks old of either sex. All mice were bred and housed in an American Association for the Accreditation of Laboratory Animal Care (AAALAC) accredited vivarium at the University of Pennsylvania. All husbandry and experimental procedures were performed according to the protocol reviewed and approved by the Institutional Animal Care and Use Committee (IACUC).

Cell preparation

Single-cell suspensions were prepared from thymi of mice by dissociation of tissue through 70 mM mesh filters (Falcon) in RPMI 1640 (Corning) +1% FBS (Gemini). DP T cells were isolated utilizing serial magnetic bead separation. First EasySep[™] Release Mouse Biotin Positive Selection Kit was utilized with biotin anti-mouse CD8a (53–6.7), followed by isolation with EasySep[™] Mouse CD4 Positive Selection Kit II. Purity of DP cells post isolation was 90% as assessed by flow cytometry.

METHOD DETAILS

Lentiviral Packaging and Transduction for NIH 3T3 cells—For TCF-1

overexpression in 3T3 cells, the cDNA encoding the short isoform of TCF-1 (p33)¹⁷ was cloned into Tet-inducible lentiviral vector pINDUCER-20 (Addgene) using Gateway cloning strategy (Gateway Clonase II, Invitrogen). Lentiviral vectors were packaged in HEK293T cells. Briefly, 4×10^6 HEK293T cells were plated in 5 mL media in 10 cm dishes on the day prior to transfection. During transfection, 3.9 µg of pINDUCER-20-TCF-1 plasmid was co-transfected with packaging plasmids, 2.6 µg of pCMVdelta and 1.3 µg of VSV-G, using 26 µL FuGene HD (Promega). The cells were returned to the incubator for 6 hours. Subsequently, the medium was changed to fresh media. Virions were collected 24 and 48 hrs after transfection, snap-frozen, and stored at -80°C for future use. NIH 3T3 cells were transduced by addition of virions to culture media supplemented with polybrene (Sigma-Aldrich, cat# H9268) at 8 mg mL⁻¹ followed by centrifugation at room temperature for 20 mins at 2000 rpm. Transduced cells were selected using 1 mg/ml G418 (Gibco) for 7 days. TCF-1 expression was induced using 500 ng/ml of doxycycline for 72 hrs. Cells which have been transduced with the same vector but have not been treated with doxycycline are referred to as 'untreated NIH-3T3' while doxycycline-treated cells are referred to as 'TCF-1 induced NIH-3T3'.

Retroviral Packaging and Transduction for TCF-1 KO in Scid.adh cell

line—CRISPR/Cas9 system was used to delete TCF-1 in Scid.adh cells. sgRNAs targeting the DNA-binding domain (HMG-box) were designed using CRISPR Targets tracks of UCSC genome browser. ACCGCAACCAGATCCTGGGTCGCA and AAACTGCGACCCAGGATCTGGTTG were used as sgRNA. sgRNA was cloned into pSL21-vex (Addgene 158230)⁶⁹, MSCV-Cas9-puro plasmid (Addgene 65655) was used for retroviral introduction of Cas9 into the cells. For retroviral packaging, 4×10^6 293T cells were plated in 4 mL DMEM media in 10 cm dishes on the day prior to transfection. Immediately before transfection, chloroquine was added to the media to a final concentration of 25 mM. The retroviral construct/empty vector and the pCL-Eco plasmid were transiently co-transfected using Lipofectamine 3000 (Invitrogen). The cells were returned to the incubator for 6 hours. Subsequently, the medium was changed to fresh media. Virions were collected 24 and 48 hrs after transfection, snap-frozen, and stored at -80° C for future use. Scid.adh cells were transduced by addition of Cas9- and sgRNA-virions to culture media supplemented with polybrene (Sigma-Aldrich, cat# H9268) at 8 mg mL⁻¹ and spinfected at 1750 rpm for 25 mins. Cas9-expressing cells were selected 4 days after spin infection with 1 μ g/mL puromycin for 7 days, followed by checking Cas9 expression on the western blot. To obtain single cell clones of the TCF-1-knockout cells, we diluted bulk

transduced cells to obtain a dilution of 1 cell in 100 µL media and plated them in 96-well plates. Knockout clones G9 and E10 were selected after performing western blot to check TCF-1 expression. Hi-C data in both clones are used to evaluate the effect of TCF-1 deletion in DN3 cell lines.

Western Blot—Western blotting was performed on whole cell lysates from Vav-Cre+, heterozygous and homozygous Tcf7–/– thymocytes as well as cells derived from Scid.adh Tcf7 KO single cell clones. Cells were lysed with 1X RIPA buffer supplemented with proteinase inhibitor cocktail. Equal numbers of cells per condition were utilized and equal volumes of lysate were loaded on a NuPAGETM 4–12% Bis-Tris gel and transferred using the iBlotTM 2 Gel Transfer Device. Membranes were blocked with 5% non fat dry milk in 1X TBST buffer followed by incubation with primary rabbit-anti mouse and HRP conjugated secondary antibodies. Blots were visualized with SuperSignalTM West Femto Maximum Sensitivity Substrate on the ChemiDocTM Imaging system.

Flow Cytometry—Single-cell suspensions were stained following standard protocols. The fluorochrome-conjugated, anti-mouse antibodies were as follows: PE CD4 (RM4-4), APC CD8a (53–6.7), BV785 CD44 (IM7), PECy7 CD25 (PC61) and APC Streptavidin. Antibodies used in the lineage cocktail (Lin) include biotinylated antibodies against GR-1 (RB6-8C5), NK1.1 (PK136), CD11b (M1/70), Ter119 (TER-119), and B220 (RA3-6B2). Cells were stained with LIVE/DEAD Fixable Aqua Dead Cell Stain Kit for discrimination of live cells. Data were collected on an LSRII running DIVA software (BD Biosciences) and were analyzed with FlowJo software v10.6.1.

ChIP-seq—ChIP-seq was performed as previously described ²⁷. Cells were fixed for 30 min in RPMI 1640 (Gibco) with 1% FBS (Sigma-Aldrich) with 1.5 mM ethylene glycol-bis (succinic acid N-hydroxysuccinimideester) (EGS) (Thermo 21565) in DMSO followed by 15 min with 1% formaldehyde (Formaldehyde solution 16% Fisher 28906) and quenched for 10 min with 0.125 M glycine. Cells were washed $2\times$ with PBS and frozen at -80° C. Crosslinked cells were lysed and then sonicated for 10 cycles at 10 sec each with 50 sec between cycles. Triton X-100 was added to a final concentration of 1% to centrifuge cleared lysates. Lysates were incubated overnight with Protein G Dynabeads (ThermoFisher 10003D) conjugated to 10 µg of anti-SMC1 Antibody (Bethyl A300-055A), 10 µg of anti-CTCF antibody (Millipore 07–729), 10 µg of anti-NIPBL antibody (Bethyl A301-779A), 10 µg of anti-H3K27ac antibody (Abcam ab4729) or 10 µg of anti-TCF-1 antibody (CST 2206S). Beads were washed and complexes were eluted for 30 min at 65°C with shaking. After reversal of cross-linking, RNase and proteinase K treatment were performed and DNA was purified and quantified. Two biological replicates were generated for each experiment. Two separate aliquot of fixed cells per condition were used as replicates for each experiment. Library preparation was carried out using NEBNext Ultra II DNA Library Prep Kit for Illumina (NEB) and were paired-end sequenced (38bp+38bp) on a NextSeq 550 (Illumina).

RNA-seq—Cells were washed once with $1 \times$ PBS before resuspending pellet in 350 µL Buffer RLT Plus (QIAGEN) with 1% 2-Mercaptoethanol (Sigma), vortexed briefly, and stored at -80° C. Subsequently, total RNA was isolated using the RNeasy Plus Micro Kit

(QIAGEN). RNA integrity numbers were determined using a TapeStation 2200 (Agilent), and all samples used for RNA-seq library preparation had RIN numbers greater than 9. Libraries were prepared using the SMARTer[®] Stranded Total RNA-seq Kit v2- Pico Input Mammalian kit (Takara). Two biological replicates were generated for each experiment. Two separate aliquot of fixed cells per condition were used as replicates for each experiment. Libraries were validated for quality and size distribution using a TapeStation 2200 (Agilent). Libraries were paired-end sequenced (38bp+38bp) on a NextSeq 550 (Illumina).

ATAC-seq—ATAC-seq was performed as previously described with minor modifications 27,70 . Fifty thousand cells were pelleted at $550 \times g$ and washed with 50 µL ice-cold 1× PBS, followed by treatment with 50 µL lysis buffer (10 mM Tris-HCl [pH 7.4], 10 mM NaCl, 3 mM MgCl2, 0.1% IGEPAL CA-630). Nuclei pellets were resuspended in 50 µL transposition reaction containing 2.5 µL Tn5 transposase (FC-121-1030; Illumina). The reaction was incubated in a 37°C heat block for 45 min. Tagmented DNA was purified using a MinElute Reaction Cleanup Kit (QIAGEN) and amplified with varying cycles, depending on the side reaction results. Libraries were purified using a QIAQuick PCR Purification Kit (QIAGEN). Libraries were validated for quality and size distribution using a TapeStation 2200 (Agilent). Libraries were paired-end sequenced (38bp+38bp) on a NextSeq 550 (Illumina).

HiChIP—HiChIP was performed as described ⁷¹ using antibody against SMC1 (Bethyl A300-055A). Briefly, 10×106 cells were crosslinked with 1% formaldehyde (Thermo Fisher Scientific, cat# 28908) for 10 min and subsequently quenched with 0.125 M glycine (Invitrogen, cat# 15527-013). Chromatin was digested using MboI restriction enzyme (NEB, cat# R0147), followed by biotin incorporation with Biotin-14-dATP (Invitrogen, cat# 19524–016) during repair, ligation, and sonication. Sheared chromatin was 4-fold diluted with ChIP dilution buffer (16.7mM Tris pH 7.5, 167mM NaCl, 1.2mM EDTA, 0.01% SDS, 1.1% Triton X-100), pre-cleared, and then incubated with SMC1 antibody at 4°C overnight. Chromatin-antibody complexes were captured by Protein-A magnetic beads (Pierce, cat# 88846) and subsequently washed with Low Salt Wash Buffer, High Salt Wash Buffer, LiCl Wash Buffer and eluted. DNA was purified with MinElute PCR Purification Kit (QIAGEN, cat# 28004) and quantified using Qubit dsDNA HS Assay Kit (Invitrogen, cat# Q32851). 50-150ng was used for capture with Dynabeads MyOne Streptavidin C-1 (Invitrogen, cat# 65001) and an appropriate amount of Tn5 enzyme (Illumina, cat# FC-121-1030) was added to captured DNA to generate the sequencing library. Libraries were validated for quality and size distribution using a TapeStation 2200 (Agilent). Paired-end sequencing (38 bp+38 bp) was performed on a NextSeq 550.

Hi-C—Hi-C libraries were generated on 10⁶ cells using with Arima-HiC+ kit (Arima Genomics) and Accel-NGS @S Plus DNA Library kit (21024 Swift Biosciences), according to the manufacturer's recommendations. Libraries were validated for quality and size distribution using Qubit dsDNA HS Assay Kit (Invitrogen, cat# Q32851) and TapeStation 2200 (Agilent). Libraries were paired-end sequenced (66bp+66bp) on NovaSeq 6000 (Illumina).

Oligopaint Probe designing—The TADs and boundaries at CD8a locus were identified using insulation score ²⁶ (as described in more details subsequently). The OligoMiner design pipeline ⁷² was then applied to design DNA FISH probes to the respective coordinates, chr6: 71163477–71432963 (TAD1) and chr6: 71440321–71825773 (TAD2). Oligopaint probes were designed to have 80 bases of homology with an average of 5 probes per kb and were purchased from Twist Bioscience. Oligopaint probes were synthesized as described previously ^{73,74}.

Oligopaint DNA FISH: Cells were incubated on 75×25 mm polysine adhesion glass slides (Electron Microscopy Sciences, cat #63412-01) with silicone isolators (Electron Microscopy Sciences, cat #70339-05) for 1 hour at RT in a humidified chamber. Cells were then fixed to the slide for 10 min with 4% formaldehyde in phosphate-buffered saline (PBS) and rinsed briefly in PBS. Slides were stored in PBS at 4°C until use.

For DNA FISH primary probe hybridization, slides were warmed to RT in PBS for 10 min. Cells were permeabilized in 0.5% Triton-PBS for 15 min. Cells were then dehydrated in an ethanol row, consisting of 2-min consecutive incubations in 70%, 90%, and 100% ethanol. The slides were then allowed to air dry for about 2 min at RT. Cells were then washed in 4XSSCT/50% formamide (0.6M NaCl, 0.06M sodium citrate, 0.2% Tween-20) for 5 min, pre-denatured in 4XSSCT/50% formamide at 92°C for 2.5 min, and then in 4XSSCT/50% formamide at 60°C for 20 min. 50 pmol of primary Oligopaint probes in hybridization buffer (10% dextran sulfate/2xSSCT/50% formamide/4% polyvinylsulfonic acid (PVSA)/1.4 mM dNTPs) were then added to the cells, covered with a 24 × 50 mm glass coverslip (Fisher Scientific, cat #22037170), and sealed with no-wrinkle rubber cement (Elmer's). Cells were denatured by placing slides on a heat block in a water bath set to 92°C for 2.5 minutes, after which slides were transferred to a humidified chamber and incubated overnight at 37°C. Approximately 16–18 hours later, coverslips were removed with a razor blade, and slides were washed in 2XSSCT (0.3M NaCl, 0.03M sodium citrate, 0.1% Tween-20) at 60°C for 15 min, 2XSSCT at RT for 10 min, and 0.2XSSC at RT for 10 min.

Secondary probes (10 pmol/25 μ L) containing fluorophores Atto-565 and Alexa-647 (IDT) were added to the slides, again resuspended in hybridization buffer containing only 10% formamide and covered with a coverslip sealed with rubber cement. Slides were incubated at RT for 2 hours in a dark, humidified chamber, followed by washes in 2XSSCT at 60°C for 5 min, 2XSSCT at RT for 5 min. All slides were stained in PBS with DAPI (0.1 mg/mL) and then washed in 2XSSC. Slides were mounted with Slowfade Gold Antifade Reagent (Invitrogen, cat# S36936) and sealed with clear fingernail polish.

Image acquisition and processing: Imaging was performed on a Leica TCS SP8 Multiphoton Confocal microscope using a 1.3 NA ×40 oil immersion objective with pixels of 541.6 nm × 541.6 nm. Fields of view were selected, such that confluence was balanced to provide maximum data points and to ensure proper cell segmentation during downstream analysis. Z-stacks were determined, such that both homologs were within the imaged space and represented 10 μ m in total axial thickness. Localizations were then recorded in 0.3 μ m steps.

Representative images were also obtained on a Leica TCS SP8 Multiphoton Confocal microscope, this time using a 1.4 NA ×63 oil immersion objective with pixels of 343.9×343.9 nm. Z-stacks were determined and recorded as with the 1.3 NA ×40 oil immersion objective. Each cell, allele, and locus for each strain were individually processed using FIJI software to generate orthogonal projections of the Z-stacks and to split channels into individual TIFs.

3D reconstructions of representative cells were rendered using IMARIS v.7.4.2 software (Bitplane AG, Switzerland). DNA FISH dots were generated using the Spots tool with a 0.8 μ m diameter, created at the intensity mass center of the fluorescent probe signal. Nuclear volume was created using the Surfaces tool with automatic settings based on the fluorescent signal from the DAPI stain.

ChIP-seq data analysis—Bowtie2 ⁵⁰ was used for alignment of ChIP-seq data. Reads aligned to the mitochondrial genome or chrY as well as reads mapping to multiple genomic loci were discarded from downstream analyses. Bigwig files were generated by bedtools ⁷⁵ genomecov and wigToBigWig normalizing tracks to tags-per-million. For peak calling, macs2 ⁵⁴ with "macs2 callpeak -c inputfile–nolambda–nomodel–keep-dup all -p 0.00001" was used. Input sample was prepared by the same approach without immunoprecipitation and used as input control for peak calling. ChIP-seq peaks from two conditions and both replicates were merged, and the number of fragments in each peak were counted with bedtools. The count data of each peak was then fed to DEseq2 for differential analysis.

RNA-seq data analysis—RNA-seq samples were aligned by STAR_2.5.0a_alpha ⁵¹ with parameters '– readFilesCommand zcat–outFilterMultimapNmax 1–outSAMtype SAM–alignEndsType Local–outReadsUnmapped Fastx–outFilterMismatchNmax 1– alignMatesGapMax 400000–sjdbGTFfile'. HTSeq v0.6.1 facilitated counting RNA-seq reads on Gencode vM11 gene models with parameters '-s yes -t exon -m intersection-nonempty'. DESeq2 was subsequently applied on gene counts to identify genes differentially expressed.

ATAC-seq data analysis—Bowtie2 was used for alignment (bowtie2 -p 20 -X2000 -t). Reads aligned to the mitochondrial genome or chrY as well as reads mapping to multiple genomic loci were discarded from downstream analyses. Additionally, Picard was used to mark and remove duplicates. Furthermore, for each ATAC-seq library the insert size was calculated by Picard. The insert size distribution of sequenced fragments had clear periodicity of approximately 200 bp, suggesting many fragments are protected by integer multiples of nucleosomes. Bigwig files were generated by bedtools genomecov and wigToBigWig normalizing tracks to tags-per-million. For peak calling, macs2 with "macs2 callpeak–nomodel -B–keep-dup all–broad–broad-cutoff 0.1 -q 0.1" was used.

HiChIP and Hi-C data analysis

<u>HiChIP data processing</u>: Raw reads for HiChIP sample were processed with HiC-Pro (version 2.11.1) ⁵⁶ to obtain putative interactions with default parameters except LIGATION_SITE = GATCGATC and GENOME_FRAGMENT generated for MboI

restriction enzyme. For the purpose of downstream analysis, ValidPairs were converted to cool files and hic files using the "hicpro2higlass.sh" and "hicpro2juicebox.sh" in utils of HiC-Pro, respectively.

<u>**Hi-C data processing:**</u> For the 3e Hi-C data during T cell development 25 , we downloaded the raw data from GSE79422 and processed it with HiC-Pro without setting the LIGATION_SITE and GENOME_FRAGMENT. For the Hi-C data we generated in wild type and TCF-1 knock out DN3 cell line, we processed the data with HiC-Pro using parameters LIGATION_SITE = GATCGATC and GENOME_FRAGMENT generated for MboI restriction enzyme, keeping other parameters as default. ValidPairs generated by HiC-Pro were further converted to cool and hic files as described above.

<u>Compartment analysis:</u> We did the compartment analysis of HiChIP and Hi-C data following the tutorial on cooltools github page (https://github.com/open2c/cooltools) and further visualized the compartment strength utilizing saddle plot implemented in cooltools. Scatter plot of PC1 values between the two different conditions was done with ggplot2 in R, of which the correlation was calculated with stat_cor() function in ggpubr package. The compartment strength was calculated with the top 30% PC1 regions representing A compartment and bottom 30% PC1 value representing B compartment. We calculated the compartment strength, AA interactions, BB interactions and AB interactions of each chromosome, and used boxplot to compare the two conditions implementing Student's t-test for statistical test.

TAD and boundary analysis: TADs and boundaries were identified with insulation score²⁶, which was implemented in cooltools "diamond-insulation" function. We calculated the genome-wide insulation score at 20 kb resolution with 500 kb window size utilizing cooltools diamond-insulation. The insulation score result was converted to bedgraph file, which was further converted to bigwig files for visualization purpose. Boundaries were identified with the bins whose boundary strength > 0.1 and were further used to define TADs with custom python script.

Common and unique boundaries between conditions and among T cell developmental stages were identified with custom python script, in which we clustered the boundaries whose minimum distance is less than 100 kb and the maximum distance between the boundaries should be within 200 kb. We generated a set of consensus boundaries based on the boundary clusters by taking the two ends of each cluster as boundary coordinates. In this way, we generated the common and unique boundaries between conditions and identified the boundaries that are shared between different T cell developmental stages. The boundaries that are shared or unique to the six T cell developmental stages were visualized with UpSetR ⁶⁰. Common and unique TADs between conditions were identified with bedtools intersect (-wao -f 0.8 -r) ⁷⁵ and followed with filtering the TADs by only keeping TADs whose distances of starts and ends in two conditions. Cooler was used to dump the contact matrix from cool files, and custom script was used to calculate the PETs within the TAD, which was divided by PETs between the TAD and the chromosome to generate the domain score.

Directional index: Matrix was generated from cool files using cooltools dump-cworld with parameter "--balancing-type IC_unity". Then directional index (DI) was calculated with script from dekker-cworld (https://github.com/dekkerlab/cworld-dekker). The results were further converted to bedgraph and bigwig files for visualization.

TCF-1 association with interaction change: In the TCF-1 association with increased intra-TAD interactions during T cell development, we identified the common TADs between five early stages and DP T cells. Then we calculated the log2 fold change of PETs within the common TADs from early stages to DP, as well as TCF-1 densities in the TADs. The relationship between TCF-1 density and increase of intra-TAD interactions was visualized with boxplot in ggplot2, and the correlation was calculated with stat_cor() function.

In the association of TCF-1 binding and domain score change in NIH3T3, we subtracted the domain scores of common TADs between TCF-1 induced and normal NIH3T3 and calculated the TCF-1 densities in the TADs. Then we plotted the relationship between these two features with boxplot in ggplot2. For the bin based analysis, we calculated the number of TCF-1 peaks within 50 kb to each bin, and further classified it according to whether there is TCF-1 binding in that bin. Then we calculate the total PETs between the bin and other regions of the TAD in both TCF-1 induced and normal NIH3T3, which was used to determine log2 fold change of interactions of the bin. We plotted the relationship between number of TCF-1 peaks within 50 kb and log2 fold change of interactions of the bins. We plotted the relationship between susing boxplot in ggplot2, and further separated the bins to with or without TCF-1 binding. We used the classified bins, and aggregated the PETs between bin pairs with same TCF-1 peaks and binding status. Log2 fold change of the pairwise interaction between the bins was calculated and visualized with python script.

Loop analysis: ValidPairs from HiC-Pro and SMC1 ChIP-seq peaks were fed to hichipper 62 to call significant interactions. Only loops with PETs >= 2 were kept for downstream analysis. The comparison of increased loops after TCF-1 induction in fibroblast between different peaks was done using violin plot and boxplot in addition to stat_compare_means() for statistical tests in ggplot2.

We used loops from mango to do the association analysis of loops with TCF-1 and CTCF ChIP-seq peaks utilizing bedtools pairtobed function. The TCF-1 and CTCF peaks were extended 5 kb at both sides. Then we plotted the loops associated with TCF-1 and CTCF peaks with venn diagram in python (https://pypi.org/project/matplotlib-venn/). Genome browser view of cohesin loops and ChIP-seq signals on TCF-1, CTCF and SMC1 were shown using IGV.

3D Pileup analysis: Local pileup analysis at different sets of peaks was done with coolpup.py ⁶³ using parameters "--pad 250 --local". The average interaction of the upright corner of pileup plots is quantified with custom python script, by parsing the results from coolpup.py. Interactions between regions in bedfiles were done with parameters "--mindist 200000 --maxdist 2000000". Pileup of loops was also plot with coolpup.py. To identify the regions that have insulation change, we quantified the average interactions between upstream and downstream of each peak. The peaks whose difference of average interactions

between two conditions greater than 0.05 will be considered change of insulation. To do multiple pileup analysis parallelly, we used GNU parallel to run the shell script.

<u>Stripe analysis:</u> We used Stripenn⁷⁶ to quantify stripiness of the stripe originating from the TCF1 cluster between NOD and C57BL/6.

<u>1D pileup analysis:</u> The pileup analysis of 1D features including insulation score, directional index, ChIP-seq and phastCons score was done with deeptools⁶¹.

<u>Visualization of 1D and 3D features at selected regions</u>: We used HiCExplorer ⁵⁹ to visualize the interactions, insulation score, genes and ChIP-seq signals of selected regions. The cool files were converted to h5 format with hicConvertFormat using parameter "-- load_raw_values". The color scales of the interaction heatmaps were normalized with total PETs.

Triangle heatmaps—Triangle heatmaps for 3D chromatin conformation data and corresponding tracks were generated using Sushi R package (version 1.28.0)

Quantification of inter-domain interactions—The inter-domain interactions marked yellow and sky blue boxes in the Sushi plots were quantified using matrix.fetch function in the cooler package⁷⁷. The square root of vanilla coverage method (VC SQRT)⁷⁸ or matrix balancing normalization⁷⁹ was used.

Detection of regions which gained or lost insulation at TCF-1 binding sites: We used custom script following the tutorial on cooltools GitHub page (https://github.com/open2c/ cooltools) to calculate the interactions in a 500 kb window centered on each peak, for both untreated and TCF-1 induced 3T3, and for WT and TCF-1 KO DN3 cells. Those peaks that have an increase or decrease of interactions between upstream and downstream of the peaks by greater than 0.05 were selected for TCF-1 induced 3T3 and TCF-1 KO DN3 cells, respectively. The pileup at these peaks were plotted using coolpup.py.

Distance to T cell development genes—We downloaded the signature genes for each T cell development stage from single cell studies of thymus in mouse ²⁸. Then calculated the distance of these genes to the closest TCF-1 and CTCF co-bound peak with bedtools closest.

Oligopaint FISH imaging analysis—The TANGO⁸⁰ plug-in of FIJI software⁸¹ was utilized for the oligopaint FISH imaging analysis. An image with LIF file extension was used as an input. The imaging analysis is composed of two steps: (1) cell/probe segmentations and (2) the measurement of the overlapping volume and minimum distance between two probes. Before the cell segmentation, *Fast Filter 3D* (median filter) and *Misc 3D Filters* (Gaussian 3D filter) were applied to the image. Then, *OTSU* method was used for cell segmentation. After cell segmentation, *Morphological Filters 3D* (Fill Holes 3D and Fill holes 2D) was applied for cells as post-filtering. For probe channels, *Fast Filters 3D* (Mean filter), *Subtract Background 2D* (radius: 5 pixels, rolling ball method) and *Misc 3D filters* (Gaussian 3D filter) were applied before segmentation. For segmentation, *Percentage of Bright Pixels* was set as 3.5%. As post-filtering, *Morphological filters 3D* and *Size and*

Edge filter (minimum volume=5) were applied. After cell segmentation, those including more than one cell were eliminated from the analysis. To measure the overlapping volume and the distance between two probes, *object colocalization* and *minimal distance* functions were utilized.

Extended Data



Extended Data Fig. 1. Loops associated with CTCF and TCF-1.

Genome browser view showing cohesin loops and CTCF, TCF-1, SMC1 binding at the *Ets1* (a) and *Tcf7*(b) loci. The loops associated with both TCF-1 and CTCF are shown in the bottom panel.



Extended Data Fig. 2. Loss of insulation and boundaries during T cell development. **a.** Summary plot and heatmap of insulation score in six T cell developmental stages at CTCF-only (red), CTCF+TCF-1 (yellow), TCF-1-only (blue) peaks and random regions as control (black), where lower value indicates higher insulation. Peaks defined in Fig

1c. **b.** Violin plot and boxplot (centre, median; box limits, upper (75th) and lower (25th) percentiles; whiskers, $1.5 \times$ interquartile range; points, outliers) showing differences in insulation score from CLP to DP at the four different sets of peaks. The comparison between different groups was done with one-sided Student's t-test. The insulation score change is significantly ($P < 2.2 \times 10^{-16}$) different between different sets of peaks. **c.** Bar plot showing the total number of boundaries in six T cell developmental stages. **d.** Upset plot showing unique and shared boundaries that are lost or gained during T cell development. **e.** Local pileup in six T cell developmental stages at the nine groups of boundaries classified in (**d**). **f.** Quantification of interactions in six T cell developmental stages between upstream and downstream regions of the nine groups of boundaries.





a. Summary plot and heatmap of insulation score in 1 Mbp regions centered at the nine groups of boundaries in six T cell developmental stages. **b.** Summary plot and heatmap of directionality index at the nine groups of boundaries in six T cell developmental stages. Cumulative distribution of PC1 values in CLP cells (**c**) and DP cells (**d**) at nine boundary groups. Cumulative distribution of CTCF only peak density (**e**), CTCF+TCF-1 peaks density (**f**), and TCF-1-only peak density (**g**) as defined in Fig. 1c at nine boundary groups **h.** Heatmap showing enrichment of CTCF only, CTCF+TCF-1, TCF-1 only peaks and random

genes highlighted in orange.

regions at nine boundary groups, as well as the H3K4me2, H3KAc, ATAC-seq and RNA-seq signals at T cell developmental stages. Signals in each row are normalized between 0 and 1. **i.** Heatmap showing the statistical test of enrichment of epigenetic features at each group of boundaries compared with conserved boundaries using Kolmogorov–Smirnov test. j. Genome browser view and contact matrix at the *Rag1/2* locus. Contact matrix is normalized according to the sequencing depth and triangles show the identified TADs in this region. Insulation score depicted as a line plot and colored according to their developmental stage as indicated in the figure legend. Genes in this region are shown with *Rag1* and *Rag2*



Extended Data Fig. 4. TCF-1+CTCF sites are evolutionarily conserved and insulated in non-T cells.

a. Summary plot and heatmap of sequence conservation using phastCons score at CTCF-only, CTCF+TCF-1, TCF-1-only peaks and random regions as control.

b. Local pileup plot of interactions using Hi-C measurements in progenitor and mature T cells in humans at homologues CTCF and TCF-1 peaks. Hi-C measurements were from human publicly available T-ALL, ETP T-ALL, and ultra-deep Hi-C in CD8⁺ T cells from a

healthy donor generated for this study. Human homologous regions for CTCF only, TCF-1 only as well as TCF-1+CTCF peaks in mice were found using liftOver.
c. Local pileup plot of interactions at CTCF only, TCF-1+CTCF, TCF-1 only peaks in different mouse cell types, including mouse embryonic stem cell (mESC), fibroblast (NIH3T3), cardiomyocyte, B cells, naïve CD4⁺, and DP T cells.

d. Local pileup plot of interactions in different human cell types from 4D Nucleome repository at the liftOver sites of CTCF only, TCF-1 only as well as CTCF+TCF-1 peaks from mice.



Extended Data Fig. 5. Differential gene expression and CTCF binding after TCF-1 overexpression in fibroblast.

a. Volcano plot of differentially expressed genes in non-induced 3T3 and $3T3^{TCF-1}$ fibroblasts. Log2 fold change and *P* values are calculated with DEseq2. *P* depicts adjusted pvalue calculated by DESeq2. **b.** Volcano plot of differential CTCF binding in non-induced 3T3 and $3T3^{TCF-1}$ fibroblasts. Log2 fold change and *P* values are calculated with DEseq2. *P* depicts adjusted pvalue calculated by DESeq2. **c.** Scatter plot of PC1 values in non-induced 3T3 and $3T3^{TCF-1}$ fibroblasts. The blue lines are where PC1 values are equal to zero, and

the red line is where PC1 values are equal in the two conditions. Pearson correlation and the two-sided significance level are shown, the PC1 values are significantly ($P < 2.2 \times$ 10^{-16}) correlated. **d.** Saddle plot showing the compartmentalization in non-induced 3T3 and 3T3^{TCF-1} fibroblasts. The regions are sorted by PC1 value from B to A compartment, and interactions between different regions are shown in the heatmap. e. Boxplot (centre, median; box limits, upper (75th) and lower (25th) percentiles; whiskers, 1.5× interquartile range; points, outliers) shows the compartment strength, BB interactions, AA interactions and AB interactions in wildtype and $Tcf7^{-/-}$ DN3s on all chromosomes (n=20). The statistical test was done using two-sided Student's t-test. (ns: not significant). f. Venn diagram showing the unique and shared boundaries non-induced 3T3 and 3T3^{TCF-1} fibroblasts. g. Summary plot and heatmap of TCF-1 ChIP-seq performed in NIH3T3 cells at unique and common boundaries between and after TCF-1 induction. The three different sets of boundaries are normalized to the same height. h. Boxplots (centre, median; box limits, upper (75th) and lower (25th) percentiles; whiskers, $1.5 \times$ interquartile range; points, outliers) showing the correlation of TCF-1 binding density in NIH3T3 cells and increase in domain score after TCF-1 overexpression. TADs (n=2573) are grouped based on the increase of domain score and the boxplots show TCF-1 peak density in each group. R and P values are calculated with two-sided Pearson correlation. The results shows TCF-1 binding is significantly ($P < 2.2 \times$ 10^{-16}) associated with domain score increase. **i.** Illustration of our computational strategy to classify TCF-1-dependent 3D genome interactions originating from TCF-1 binding. Genomic regions were divided into bins and classified based on the number of TCF-1 peaks within 50 kb, as well as TCF-1 binding status in the bin. For every genomic bin, we therefore calculated the number of TCF-1 peaks in the 50 kbp neighborhood of the bin and additionally classified these bins into TCF-1 bound and unbound regions. j. Boxplots (centre, median; box limits, upper (75th) and lower (25th) percentiles; whiskers, 1.5× interquartile range; points, outliers) show correlation of interactions at bins with different number of TCF-1 binding events within their 50 kb neighborhood. Each bin itself is further divided based on TCF-1 occupancy. k. The greatest increase in 3D interactions after TCF-1 expression in fibroblasts occurs when TCF-1 occupies both anchors and has high density at anchors' neighboring regions. We calculated the extent of increase in interactions between 10kbp bin pairs which were grouped based on the status of TCF-1 binding and the number of TCF-1 binding events in their 50kbp neighborhood. I. Violin plot and boxplot (centre, median; box limits, upper (75th) and lower (25th) percentiles; whiskers, $1.5 \times$ interquartile range; points, outliers) showing the number of loops after TCF-1 overexpression in 3T3 at anchors that are bound by CTCF only, CTCF+TCF-1, TCF-1 only and random regions. The statistical test was done with two-sided Student's t-test. The results show that the gain of loops after TCF-1 overexpression are significantly ($P < 2.2 \times 10^{-16}$) different between different sets of peaks.

Extended Data Fig. 6. 3D genome reorganization after TCF-1 deletion in DN3 and DPs. a. Western blot of TCF-1 in DN3s in which TCF-1 was disrupted using CRISPR/Cas9. Single cell clones in bold indicate those utilized for further experiments. Experiments were carried out twice and similar results were obtained.

b. Illustration of breeding strategy for disruption of *Tcf*7 in mice by crossing Vav-Cre with *Tcf*7 floxed mice, generating mice in which TCF-1 is conditionally ablated in all hematopoietic cells.

c-d. Western blot of TCF-1 in thymocytes from homozygous fl/fl cre+ ($Tcf7^{-/-}$), heterozygous fl/+ cre+ (N=2), and cre+ mice. (**c**) Flow cytometric analysis of thymocytes from Vav cre+ control and $Tcf7^{-/-}$ experimental mice. Top panel shows CD4⁺ and CD8⁺ populations and is pre-gated on lymphocytes, live, and single cells. Bottom panel shows DN populations DN1-DN4 (upper left to lower left quadrant clockwise) as measured based on CD44 and CD25 expression and is pre-gated on lymphocytes, live, single cells and lineage negative cells (**d**).

e-f. Scatter plot showing A/B compartment distribution using correlation of PC1 values between wildtype and $Tcf7^{-/-}$ DN3s (**e**) and DPs (**f**). Blue lines are PC1 equals zero, and red line is where PC1 are equal in two conditions. Pearson correlation coefficients and *P*-values are shown.

g. Saddle plot shows the compartmentalization in wildtype and $Tcf7^{-/-}$ DN3s. The regions are sorted by PC1 value from B to A compartment, and interactions between different regions are shown in the heatmap. One Hi-C experiment was performed in the wildtype condition and two Hi-C experiments were performed in two distinct $Tcf7^{-/-}$ DN3 clones. **h.** Data are shown as boxplots (centre, median; box limits, upper (75th) and lower (25th) percentiles; whiskers, $1.5 \times$ interquartile range; points, outliers) showing the compartment strength, BB interactions, AA interactions and AB interactions in wildtype and $Tcf7^{-/-}$ DN3s (n=20 mouse chromosomes). The statistical test was done using two-sided Student's t-test. (ns: not significant, *: P < 0.05).

i-j. Venn diagram showing the unique and shared boundaries between wildtype and $Tcf7^{-/-}$ DN3s (i) and DP (j).

k-l. Scatter plot showing changes in gene expression located in the top 50 TADs that lost domain score in DN3 (k) and DP (l) T cells. Genes that were significantly (P < 0.05, abs(log2FoldChange) > 0.5) differentially expressed were shown in red. **m.** Gene-ontology analysis of genes in the top 50 TADs that gained domain score and the top 50 TADs that lost domain score after TCF-1 deletion in DN3s using metaScape. T cell-specific ontology terms are marked in red.

Extended Data Fig. 7. Reorganization of interferon genes by TCF-1.

a,b,d,e. Contact matrix and genome browser views of ultra-deep Hi-C measurements at interferon-induced gene cluster (genes marked in orange) using two independent clones for deleting TCF-1 using CRISPR/Cas9 in DN3 (**a**), comparing SMC1 HiChIP in DPs of C57BL/6 and NOD mice (**b**). We used Stripenn to quantify stripiness of the stripe originating from the TCF1 cluster, which showed that NOD has a stripe score of 2.14, while C57BL/6 is -2.3. SMC1 HiChIP in TCF-1 induction in fibroblasts (**d**), and ultra-deep Hi-C in wildtype and *Tcf7*^{-/-} DPs (**e**). The browser view focuses on a TAD that lose intra-TAD interactions after TCF-1 deletion in both replicates, which also have a cluster of TCF-1 binding (grey highlighted) in wildtype DN3s. The CTCF and SMC1 binding in both conditions are also shown. **c**. Heatmap showing the row normalized gene expression level from DPs in NOD and C57BL/6 of the interferon induced genes in the TAD with different intra-TAD interactions in C57BL/6 and NOD mice. Orange bars represent genomic coordinates of interferon genes.

Wang et al.

Page 31

Observed / Expected

Extended Data Fig. 8. TCF-1 ChIP-seq comparison in DP T and DN3 T cells.

a. Venn diagram of overlapping and unique bound regions by TCF-1 ChIP-seq thymocytes, DN3s and $3T3^{TCF-1}$. **b.** Local pileup plot of long-range interactions using ultra-deep Hi-C in wildtype and two $Tcf7^{-/-}$ DN3 clones at a subset of CTCF+TCF-1 co-bound, as well as TCF-1-only peaks that gain insulation in $Tcf7^{-/-}$ DN3s. The two classes of peaks were defined using TCF-1 and CTCF ChIP-seq in thymocytes and DPs, respectively as in Fig. 1. These peaks were further selected based on the decrease of average interactions between the upstream and downstream of the peaks by at least 0.05 after TCF-1 deletion. The numbers are the average observed/expected interactions in the upper right square, which is the interactions between the upstream and downstream of the peaks.

c. Local pileup interactions in wildtype and *Bcl11b* deficient naïve CD4 T^+ cells at the CTCF and TCF-1 co-bound, as well as TCF-1 only peaks.

Wang et al.

Page 32

Extended Data Fig. 9. Oligopaint 3D FISH corroborates the role of TCF-1 on chromatin interactions at the Cd8 locus

a-b. Contact matrix plot of Hi-C data sets at the *Cd8a-Cd8b1* locus in NIH3T3 fibroblasts (**a**) and DN3s (**b**) (n=7221 genomic interactions). Inter-domain interactions were quantified by boxplots. Two sided Paired wilcoxon ranksum test was performed. Oligopaint probes for TAD1 (green) and TAD2 (magenta) are depicted. Two-sided Wilcoxon rank-sum test *P*-values are shown for boxplots.

c-d. Box plot showing spatial distance (**c**) and spatial overlap (**d**) between TAD1 and TAD2 compared between wildtype (N=2) and TCF-1-deficient (N=3) of DPs in biological mouse replicates. Spatial distance and overlap were calculated as in (Fig. 5d–e). Number of cells used for imaging analysis per mouse is depicted in parenthesis. **a-d** Data are shown as boxplots (centre, median; box limits, upper (75th) and lower (25th) percentiles; whiskers, $1.5 \times$ interquartile range; points, outliers)

Wang et al.

Extended Data Fig. 10. Recruitment of cohesin at TCF-1 binding sites.

a. Volcano plot shows the differential CTCF binding in wildtype and $Tcf7^{-/-}$ DN3s. Red indicates stronger binding after TCF-1 deletion. Log2 fold change and P values are calculated with DEseq2. *P* depicts adjusted pvalue calculated by DESeq2.

b. Volcano plot showing the differential SMC1 binding in wildtype and $Tcf7^{-/-}$ DN3s. Log2 fold change and P values are calculated with DEseq2. *P* depicts adjusted pvalue calculated by DESeq2. Red indicates stronger binding after TCF-1 deletion. **c.** Enriched motifs from HOMER at the gained or lost SMC1 peaks after TCF-1 deletion in DN3 cells using random background. The most significantly enriched motifs and associated P values are shown. *P* values are calculated using hypergenometric test.

d. Cumulative distribution of genomic distance between 2,042 TCF-1 dependent SMC1 and NIPBL co-bound enhancers or 2,042 randomly selected genomic regions to 988 dynamic

boundaries with TCF-1 and CTCF co-binding. Kolmogorov-Smirnov test *P*-value is shown for cumulative distribution plot.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank helpful discussions with R. B. Faryabi, K. Zaret, A. Karnay, E.J.Wherry, and R. Jain. We would like to thank J. Shi and his lab for help and discussion about the CRISPR/Cas9 plasmids. This work was supported by NIH grants UC4 DK112217, U01DK11221702A1, R01HL145754, U01DK127768, U01DA052715, the Burroughs Wellcome Fund, the Chan Zuckerberg Initiative, W. W. Smith Charitable Trust, the Penn Epigenetics Institute pilot and the Sloan Foundation awards to G.V.

Data availability

Genomics data generated in this study is publicly available on GEO: GSE178348. Oligopaint FISH data generated in this study are provided as Source Data.

References

- Beagan JA & Phillips-Cremins JE On the existence and functionality of topologically associating domains. Nat Genet 52, 8–16, doi:10.1038/s41588-019-0561-1 (2020). [PubMed: 31925403]
- Dixon JR et al. Chromatin architecture reorganization during stem cell differentiation. Nature 518, 331–336, doi:10.1038/nature14222 (2015). [PubMed: 25693564]
- 3. Dowen JM et al. Control of cell identity genes occurs in insulated neighborhoods in mammalian chromosomes. Cell 159, 374–387, doi:10.1016/j.cell.2014.09.030 (2014). [PubMed: 25303531]
- Hnisz D, Shrinivas K, Young RA, Chakraborty AK & Sharp PA A Phase Separation Model for Transcriptional Control. Cell 169, 13–23, doi:10.1016/j.cell.2017.02.007 (2017). [PubMed: 28340338]
- 5. Nora EP et al. Spatial partitioning of the regulatory landscape of the X-inactivation centre. Nature 485, 381–385, doi:10.1038/nature11049 (2012). [PubMed: 22495304]
- Dixon JR et al. Topological domains in mammalian genomes identified by analysis of chromatin interactions. Nature 485, 376–380, doi:10.1038/nature11082 (2012). [PubMed: 22495300]
- Hansen AS CTCF as a boundary factor for cohesin-mediated loop extrusion: evidence for a multistep mechanism. Nucleus 11, 132–148, doi:10.1080/19491034.2020.1782024 (2020). [PubMed: 32631111]
- Stadhouders R, Filion GJ & Graf T Transcription factors and 3D genome conformation in cell-fate decisions. Nature 569, 345–354, doi:10.1038/s41586-019-1182-7 (2019). [PubMed: 31092938]
- Stadhouders R et al. Transcription factors orchestrate dynamic interplay between genome topology and gene regulation during cell reprogramming. Nat Genet 50, 238–249, doi:10.1038/ s41588-017-0030-7 (2018). [PubMed: 29335546]
- Weintraub AS et al. YY1 Is a Structural Regulator of Enhancer-Promoter Loops. Cell 171, 1573– 1588 e1528, doi:10.1016/j.cell.2017.11.008 (2017). [PubMed: 29224777]
- Di Giammartino DC et al. KLF4 is involved in the organization and regulation of pluripotencyassociated three-dimensional enhancer networks. Nat Cell Biol 21, 1179–1190, doi:10.1038/ s41556-019-0390-6 (2019). [PubMed: 31548608]
- Johanson TM et al. Transcription-factor-mediated supervision of global genome architecture maintains B cell identity. Nat Immunol 19, 1257–1264, doi:10.1038/s41590-018-0234-8 (2018). [PubMed: 30323344]
- Singh H, Khan AA & Dinner AR Gene regulatory networks in the immune system. Trends Immunol 35, 211–218, doi:10.1016/j.it.2014.03.006 (2014). [PubMed: 24768519]

- 14. Allman D et al. Thymopoiesis independent of common lymphoid progenitors. Nat Immunol 4, 168–174, doi:10.1038/ni878 (2003). [PubMed: 12514733]
- Li L, Leid M & Rothenberg EV An early T cell lineage commitment checkpoint dependent on the transcription factor Bcl11b. Science 329, 89–93, doi:10.1126/science.1188989 (2010). [PubMed: 20595614]
- Kueh HY et al. Asynchronous combinatorial action of four regulatory factors activates Bcl11b for T cell commitment. Nat Immunol 17, 956–965, doi:10.1038/ni.3514 (2016). [PubMed: 27376470]
- Johnson JL et al. Lineage-Determining Transcription Factor TCF-1 Initiates the Epigenetic Identity of T Cells. Immunity 48, 243–257 e210, doi:10.1016/j.immuni.2018.01.012 (2018). [PubMed: 29466756]
- Emmanuel AO et al. TCF-1 and HEB cooperate to establish the epigenetic and transcription profiles of CD4(+)CD8(+) thymocytes. Nat Immunol 19, 1366–1378, doi:10.1038/ s41590-018-0254-4 (2018). [PubMed: 30420627]
- Giese K, Cox J & Grosschedl R The HMG domain of lymphoid enhancer factor 1 bends DNA and facilitates assembly of functional nucleoprotein structures. Cell 69, 185–195, doi:10.1016/0092-8674(92)90129-z (1992). [PubMed: 1555239]
- 20. Love JJ et al. Structural basis for DNA bending by the architectural transcription factor LEF-1. Nature 376, 791–795, doi:10.1038/376791a0 (1995). [PubMed: 7651541]
- 21. Shan Q et al. Tcf1 and Lef1 provide constant supervision to mature CD8(+) T cell identity and function by organizing genomic architecture. Nat Commun 12, 5863, doi:10.1038/ s41467-021-26159-1 (2021). [PubMed: 34615872]
- Zhou Y et al. EBF1 nuclear repositioning instructs chromatin refolding to promote therapy resistance in T leukemic cells. Mol Cell 82, 1003–1020 e1015, doi:10.1016/j.molcel.2022.01.015 (2022). [PubMed: 35182476]
- Antoszewski M et al. Tcf1 is essential for initiation of oncogenic Notch1-driven chromatin topology in T-ALL. Blood 139, 2483–2498, doi:10.1182/blood.2021012077 (2022). [PubMed: 35020836]
- 24. Dose M et al. beta-Catenin induces T-cell transformation by promoting genomic instability. Proc Natl Acad Sci U S A 111, 391–396, doi:10.1073/pnas.1315752111 (2014). [PubMed: 24371308]
- Hu G et al. Transformation of Accessible Chromatin and 3D Nucleome Underlies Lineage Commitment of Early T Cells. Immunity 48, 227–242 e228, doi:10.1016/j.immuni.2018.01.013 (2018). [PubMed: 29466755]
- 26. Crane E et al. Condensin-driven remodelling of X chromosome topology during dosage compensation. Nature 523, 240–244, doi:10.1038/nature14450 (2015). [PubMed: 26030525]
- 27. Fasolino M et al. Genetic Variation in Type 1 Diabetes Reconfigures the 3D Chromatin Organization of T Cells and Alters Gene Expression. Immunity 52, 257–274 e211, doi:10.1016/ j.immuni.2020.01.003 (2020). [PubMed: 32049053]
- Kernfeld EM et al. A Single-Cell Transcriptomic Atlas of Thymus Organogenesis Resolves Cell Types and Developmental Maturation. Immunity 48, 1258–1270 e1256, doi:10.1016/ j.immuni.2018.04.015 (2018). [PubMed: 29884461]
- Zhang JA, Mortazavi A, Williams BA, Wold BJ & Rothenberg EV Dynamic transformations of genome-wide epigenetic marking and transcriptional control establish T cell identity. Cell 149, 467–482, doi:10.1016/j.cell.2012.01.056 (2012). [PubMed: 22500808]
- 30. Kloetgen A et al. Three-dimensional chromatin landscapes in T cell acute lymphoblastic leukemia. Nat Genet 52, 388–400, doi:10.1038/s41588-020-0602-9 (2020). [PubMed: 32203470]
- 31. Dekker J et al. The 4D nucleome project. Nature 549, 219–226, doi:10.1038/nature23884 (2017). [PubMed: 28905911]
- Krijger PH et al. Cell-of-Origin-Specific 3D Genome Structure Acquired during Somatic Cell Reprogramming. Cell Stem Cell 18, 597–610, doi:10.1016/j.stem.2016.01.007 (2016). [PubMed: 26971819]
- Dionne CJ et al. Subversion of T lineage commitment by PU.1 in a clonal cell line system. Dev Biol 280, 448–466, doi:10.1016/j.ydbio.2005.01.027 (2005). [PubMed: 15882585]
- Forcato M et al. Comparison of computational methods for Hi-C data analysis. Nat Methods 14, 679–685, doi:10.1038/nmeth.4325 (2017). [PubMed: 28604721]

- Eres IE & Gilad Y A TAD Skeptic: Is 3D Genome Topology Conserved? Trends Genet 37, 216– 223, doi:10.1016/j.tig.2020.10.009 (2021). [PubMed: 33203573]
- Beliveau BJ et al. Single-molecule super-resolution imaging of chromosomes and in situ haplotype visualization using Oligopaint FISH probes. Nat Commun 6, 7147, doi:10.1038/ncomms8147 (2015). [PubMed: 25962338]
- 37. Beliveau BJ et al. Versatile design and synthesis platform for visualizing genomes with Oligopaint FISH probes. Proc Natl Acad Sci U S A 109, 21301–21306, doi:10.1073/pnas.1213818110 (2012). [PubMed: 23236188]
- Ollion J, Cochennec J, Loll F, Escude C & Boudier T TANGO: a generic tool for high-throughput 3D image analysis for studying nuclear organization. Bioinformatics 29, 1840–1841, doi:10.1093/ bioinformatics/btt276 (2013). [PubMed: 23681123]
- 39. Ciosk R et al. Cohesin's binding to chromosomes depends on a separate complex consisting of Scc2 and Scc4 proteins. Mol Cell 5, 243–254, doi:10.1016/s1097-2765(00)80420-7 (2000). [PubMed: 10882066]
- 40. Murayama Y & Uhlmann F Biochemical reconstitution of topological DNA binding by the cohesin ring. Nature 505, 367–371, doi:10.1038/nature12867 (2014). [PubMed: 24291789]
- Petela NJ et al. Scc2 Is a Potent Activator of Cohesin's ATPase that Promotes Loading by Binding Scc1 without Pds5. Mol Cell 70, 1134–1148 e1137, doi:10.1016/j.molcel.2018.05.022 (2018). [PubMed: 29932904]
- 42. Vian L et al. The Energetics and Physiological Impact of Cohesin Extrusion. Cell 173, 1165–1178 e1120, doi:10.1016/j.cell.2018.03.072 (2018). [PubMed: 29706548]
- Fudenberg G et al. Formation of Chromosomal Domains by Loop Extrusion. Cell Rep 15, 2038– 2049, doi:10.1016/j.celrep.2016.04.085 (2016). [PubMed: 27210764]
- 44. Kueng S et al. Wapl controls the dynamic association of cohesin with chromatin. Cell 127, 955–967, doi:10.1016/j.cell.2006.09.040 (2006). [PubMed: 17113138]
- 45. Rao SS et al. A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. Cell 159, 1665–1680, doi:10.1016/j.cell.2014.11.021 (2014). [PubMed: 25497547]
- 46. Zhu Y, Denholtz M, Lu H & Murre C Calcium signaling instructs NIPBL recruitment at active enhancers and promoters via distinct mechanisms to reconstruct genome compartmentalization. Genes Dev 35, 65–81, doi:10.1101/gad.343475.120 (2021). [PubMed: 33334824]
- Beagan JA et al. Three-dimensional genome restructuring across timescales of activity-induced neuronal gene expression. Nat Neurosci 23, 707–717, doi:10.1038/s41593-020-0634-6 (2020). [PubMed: 32451484]
- Petrovic J et al. Oncogenic Notch Promotes Long-Range Regulatory Interactions within Hyperconnected 3D Cliques. Mol Cell 73, 1174–1190 e1112, doi:10.1016/j.molcel.2019.01.006 (2019). [PubMed: 30745086]
- Yoshida H et al. The cis-Regulatory Atlas of the Mouse Immune System. Cell 176, 897–912 e820, doi:10.1016/j.cell.2018.12.036 (2019). [PubMed: 30686579]
- Langmead B & Salzberg SL Fast gapped-read alignment with Bowtie 2. Nat Methods 9, 357–359, doi:10.1038/nmeth.1923 (2012). [PubMed: 22388286]
- 51. Dobin A et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21, doi:10.1093/ bioinformatics/bts635 (2013). [PubMed: 23104886]
- Anders S, Pyl PT & Huber W HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166–169, doi:10.1093/bioinformatics/btu638 (2015). [PubMed: 25260700]
- Love MI, Huber W & Anders S Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15, 550, doi:10.1186/s13059-014-0550-8 (2014). [PubMed: 25516281]
- Shang Y et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol 9, R137, doi:10.1186/ gb-2008-9-9-r137 (2008). [PubMed: 18798982]
- 55. Heinz S et al. Simple combinations of lineage-determining transcription factors prime cisregulatory elements required for macrophage and B cell identities. Mol Cell 38, 576–589, doi:10.1016/j.molcel.2010.05.004 (2010). [PubMed: 20513432]

- 56. Servant N et al. HiC-Pro: an optimized and flexible pipeline for Hi-C data processing. Genome Biol 16, 259, doi:10.1186/s13059-015-0831-x (2015). [PubMed: 26619908]
- 57. Zhou Y et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun 10, 1523, doi:10.1038/s41467-019-09234-6 (2019). [PubMed: 30944313]
- Durand NC et al. Juicer Provides a One-Click System for Analyzing Loop-Resolution Hi-C Experiments. Cell Syst 3, 95–98, doi:10.1016/j.cels.2016.07.002 (2016). [PubMed: 27467249]
- Wolff J et al. Galaxy HiCExplorer: a web server for reproducible Hi-C data analysis, quality control and visualization. Nucleic Acids Res 46, W11–W16, doi:10.1093/nar/gky504 (2018). [PubMed: 29901812]
- Conway JR, Lex A & Gehlenborg N UpSetR: an R package for the visualization of intersecting sets and their properties. Bioinformatics 33, 2938–2940, doi:10.1093/bioinformatics/btx364 (2017). [PubMed: 28645171]
- Ramirez F, Dundar F, Diehl S, Gruning BA & Manke T deepTools: a flexible platform for exploring deep-sequencing data. Nucleic Acids Res 42, W187–191, doi:10.1093/nar/gku365 (2014). [PubMed: 24799436]
- 62. Lareau CA & Aryee MJ hichipper: a preprocessing pipeline for calling DNA loops from HiChIP data. Nat Methods 15, 155–156, doi:10.1038/nmeth.4583 (2018). [PubMed: 29489746]
- Flyamer IM, Illingworth RS & Bickmore WA Coolpup.py: versatile pile-up analysis of Hi-C data. Bioinformatics 36, 2980–2985, doi:10.1093/bioinformatics/btaa073 (2020). [PubMed: 32003791]
- Carleton M et al. Signals transduced by CD3epsilon, but not by surface pre-TCR complexes, are able to induce maturation of an early thymic lymphoma in vitro. J Immunol 163, 2576–2585 (1999). [PubMed: 10452996]
- 65. de Boer J et al. Transgenic mice with hematopoietic and lymphoid specific expression of Cre. Eur J Immunol 33, 314–325, doi:10.1002/immu.200310005 (2003). [PubMed: 12548562]
- 66. Ogilvy S et al. Promoter elements of vav drive transgene expression in vivo throughout the hematopoietic compartment. Blood 94, 1855–1863 (1999). [PubMed: 10477714]
- 67. Shimshek DR et al. Codon-improved Cre recombinase (iCre) expression in the mouse. Genesis 32, 19–26, doi:10.1002/gene.10023 (2002). [PubMed: 11835670]
- 68. Yang Q et al. TCF-1 upregulation identifies early innate lymphoid progenitors in the bone marrow. Nat Immunol 16, 1044–1050, doi:10.1038/ni.3248 (2015). [PubMed: 26280998]
- 69. Chen Z et al. In vivo CD8(+) T cell CRISPR screening reveals control by Fli1 in infection and cancer. Cell 184, 1262–1280 e1222, doi:10.1016/j.cell.2021.02.019 (2021). [PubMed: 33636129]
- Buenrostro JD, Giresi PG, Zaba LC, Chang HY & Greenleaf WJ Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat Methods 10, 1213–1218, doi:10.1038/nmeth.2688 (2013). [PubMed: 24097267]
- Mumbach MR et al. HiChIP: efficient and sensitive analysis of protein-directed genome architecture. Nat Methods 13, 919–922, doi:10.1038/nmeth.3999 (2016). [PubMed: 27643841]
- Beliveau BJ et al. OligoMiner provides a rapid, flexible environment for the design of genomescale oligonucleotide in situ hybridization probes. Proc Natl Acad Sci U S A 115, E2183–E2192, doi:10.1073/pnas.1714530115 (2018). [PubMed: 29463736]
- Moffitt JR & Zhuang X RNA Imaging with Multiplexed Error-Robust Fluorescence In Situ Hybridization (MERFISH). Methods Enzymol 572, 1–49, doi:10.1016/bs.mie.2016.03.020 (2016). [PubMed: 27241748]
- 74. Rosin LF, Nguyen SC & Joyce EF Condensin II drives large-scale folding and spatial partitioning of interphase chromosomes in Drosophila nuclei. PLoS Genet 14, e1007393, doi:10.1371/ journal.pgen.1007393 (2018). [PubMed: 30001329]
- 75. Quinlan AR & Hall IM BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841–842, doi:10.1093/bioinformatics/btq033 (2010). [PubMed: 20110278]
- 76. Yoon S, Chandra A and Vahedi G Stripenn detects architectural stripes from chromatin conformation data using computer vision. Nature Communications 3 (2022).
- Abdennur N & Mirny LA Cooler: scalable storage for Hi-C data and other genomically labeled arrays. Bioinformatics 36, 311–316, doi:10.1093/bioinformatics/btz540 (2020). [PubMed: 31290943]

- 78. Rao SSP et al. A 3D Map of the Human Genome at Kilobase Resolution Reveals Principles of Chromatin Looping. Cell 159, 1665–1680, doi:10.1016/j.cell.2014.11.021 (2014). [PubMed: 25497547]
- 79. Imakaev M et al. Iterative correction of Hi-C data reveals hallmarks of chromosome organization. Nat Methods 9, 999–+, doi:10.1038/Nmeth.2148 (2012). [PubMed: 22941365]
- Ollion J, Cochennec J, Loll F, Escude C & Boudier T TANGO: a generic tool for high-throughput 3D image analysis for studying nuclear organization. Bioinformatics 29, 1840–1841, doi:10.1093/ bioinformatics/btt276 (2013). [PubMed: 23681123]
- Schindelin J et al. Fiji: an open-source platform for biological-image analysis. Nat Methods 9, 676–682, doi:10.1038/Nmeth.2019 (2012). [PubMed: 22743772]

```
Page 39
```


Fig. 1. TCF-1 is associated with intra-TAD interactions and cohesin loops.

a. Box plots showing the association between TCF-1 binding density and log2 fold change difference in intra-TAD interactions between DP and CLP-to-DN4 (bottom) and schematic of T cell developmental stages (top). Long range interactions at various T cell developmental stages were measured using Hi-C²⁶. Intra-TAD interactions were calculated based on TADs detected in DP T cells (n=3023), and peak density were calculated with number of TCF-1 peaks per 1 Mbp region. TCF-1 peaks were defined from TCF-1 ChIP-seq in thymocytes²⁵. Data are shown as boxplots (centre, median; box limits, upper (75th) and lower (25th) percentiles; whiskers, 1.5× interquartile range; points, outliers). *P* value was calculated with

two-sided Spearman correlation. **b.** Venn diagram showing the total number of cohesin loops measured by SMC1 HiChIP and the proportion of them co-bound by CTCF and/or TCF-1 at least on one anchor. The four classes of peaks were defined using CTCF ChIP-seq in DPs²⁹ and publicly available TCF-1 ChIP-seq in thymocytes²⁵. **c.** Venn diagram showing the number of TCF-1 and CTCF peaks, and the overlap between them in DPs. **d.** Seq-logos demonstrating motif enrichment using random background based on homer analysis at TCF-1+CTCF, CTCF-only and TCF-1-only sites in DPs. *P* values are calculated using hypergenometric test. **e.** Genome browser view showing the association of CTCF and TCF-1 peaks with cohesin loops at the *Cd8a* and *Cd8b1* locus. Loops co-bound by CTCF and TCF-1 at least on one anchor are shown in the bottom panel. **f.** Pileups of interactions between pairs of T cell developmental genes and CTCF only, TCF-1+CTCF, TCF-1-only peaks and random regions within 100kbp windows. T cell genes were defined from single-cell RNA-seq analysis of the thymus³⁰ ("T Cell Subset Markers", Table S2 in ref³⁰). The number in each box indicates the strength of interaction at the center pairing TSS of T cell genes and different sets of peaks.

Wang et al.

Fig. 2. TCF-1+CTCF sites earmark weakening of insulated neighborhoods.

a. Heatmap showing local pileup interactions using Hi-C data at CTCF-only, CTCF+TCF-1, TCF-1-only peaks and random regions as control. The horizontal line and the vertical line of each plot are the 500 kb region centered on different peak groups.

b. Heatmap showing average insulation score during T cell development at the CTCF only, CTCF+TCF-1 co-bound, TCF-1 only peaks and random regions as control.

c. Boxplots showing distance of marker genes of T cell developmental stages to TCF-1+CTCF peaks. Data are shown as boxplots (centre, median; box limits, upper (75th) and lower (25th) percentiles; whiskers, $1.5 \times$ interquartile range; points, outliers). The comparison between different stages was done with two-sided Wilcoxon signed-rank test. The distance between these markder genes and TCF-1+CTCF peaks significantly ($P < 2.22 \times 10^{-16}$) changed except between DN1 and DN2. Selection of marker genes as described in Fig. 1g.

d-e Genome browser view showing the interactions at Cd3d-e (**d**) and CD8a, b1 (**e**) loci during T cell development, as well as TCF-1 and CTCF binding events in DPs. Triangles in the heatmap represent TADs called with cooltools. Boundaries are marked as vertical lines. Insulation score in each T cell developmental stage is shown as a line plot and colored according to their developmental stage as indicated in the heatmap legend. Heatmaps are

normalized with sequencing depth and ChIP-seq tracks are normalized with count per million (CPM).

Fig. 3. Gain and loss of TCF-1 reshapes long-range interactions.

a. Heatmaps showing the aggregate of interactions across invariant TADs using SMC1 HiChIP in non-induced 3T3 and $3T3^{TCF-1}$. TADs are rescaled and normalized using GENOVA. One HiChIP experiment was performed per experimental condition. **b.** Scatter plot showing domain scores in non-induced 3T3 and $3T3^{TCF-1}$. One-sided paired Student's t-test assesses that domain scores are significantly (*P*<2.21e-16) higher in $3T3^{TCF-1}$ compared with non-induced 3T3.

c. Cumulative distribution plot showing the increase of interactions in genomic bins with TCF-1+CTCF or other groups. Comparisons between different groups using two-sided Kolmogorov–Smirnov test evaluates the significance of the difference. TCF-1+CTCF sites gained significantly ($P < 2.2 \times 10^{-16}$) more interactions than other groups.

d. Contact matrix and genome browser view of the TAD encompassing the *Irf2bp2* locus in 3T3.

e. Saddle plot showing the compartmentalization across all chromosomes in wildtype and $Tcf7^{-/-}$ DPs based on Hi-C measurements. One Hi-C experiment was performed per genotype.

f. Data are shown as boxplots (centre, median; box limits, upper (75th) and lower (25th) percentiles; whiskers, $1.5 \times$ interquartile range; points, outliers) showing the compartment strength, BB interactions, AA interactions and AB interactions in wildtype and *Tcf7*^{-/-} DPs (n=20 mouse chromosomes). The statistical test was done using two-sided Student's t-test. (ns: not significant, **P*< 0.05, ****P*<0.001).

g. Scatter plot showing domains scores in DN3s and DPs. The red line represents equal domain scores in two conditions. One-sided paired Student's t-test shows that domain score is significantly different in wildtype DN3s and DPs compared with $Tcf7^{-/-}$ cells (*P*<2.21e-16). One Hi-C experiment was performed in the wildtype condition and two Hi-C experiments were performed in two distinct $Tcf7^{-/-}$ DN3 clones.

h. Gene-ontology analysis of genes in the top 50 TADs that gain domain score and the top 50 TADs that lose domain score after TCF-1 deletion in DP T cells using metaScape. **i.** Contact matrix and genome browser view of the TAD encompassing *Irf2bp2* that lost substantial intra-TAD interactions in $Tcf7^{-/-}$ DPs.

Wang et al.

Page 45

Fig. 4. TCF-1 is required to dismantle boundaries.

a. Local pileup plot of long-range interactions using SMC1 HiChIP in non-induced 3T3 and 3T3^{TCF-1} at a subset of CTCF+TCF-1 and TCF-1 only peaks which lost insulation in 3T3^{TCF-1}. The two classes of peaks were defined using TCF-1 and CTCF ChIP-seq in 3T3^{TCF-1}.

b. Summary plot and heatmap of insulation score in non-induced 3T3 and $3T3^{TCF-1}$. **c.** Local pileup plot of long-range interactions using ultra-deep Hi-C in wildtype and $Tcf7^{-/-}$ DN3 at a subset of CTCF+TCF-1 and TCF-1 only peaks that gain insulation in $Tcf7^{-/-}$ DN3. The two classes of peaks were defined using TCF-1 and CTCF ChIP-seq in thymocytes and DPs, respectively.

d. Summary plot and heatmap showing insulation score in wildtype and $Tcf7^{-/-}$ DN3.

e. Local pileup plot of long-range interactions using ultra-deep Hi-C in wildtype and $Tcf7^{-/-}$ DPs at a subset of CTCF+TCF-1 and TCF-1 only peaks that gained insulation in $Tcf7^{-/-}$ DPs.

f. Summary plot and heatmap showing insulation score in wildtype and $Tcf7^{-/-}$ DPs at a subset of CTCF+TCF-1 and TCF-1 only peaks that gained insulation after TCF-1 deletion in DPs.

g-i. Contact matrix of HiChIP and Hi-C data at the *Rtkn, II22, and II17d* loci in NIH3T3 (**g**) and DN3 (**h**), and DPs (**i**) respectively. Inter-domain interactions are quantified by boxplots (n=1080 (**g**), 3404 (**h**) and 3300 genomic interactions (**i**) for $3T3^{TCF-1}$, DN3 and DPs, respectively; centre, median; box limits, upper (75th) and lower (25th) percentiles; whiskers, $1.5 \times$ interquartile range; points, outliers). Two sided Paired wilcoxon ranksum test was performed.

Wang et al.

Fig. 5. 3D FISH reveals TCF-1 dependent TAD intermingling at the *CD8a* locus in DPs. a. Contact matrix of Hi-C data at the *Cd8a-Cd8b1* locus which includes the location of Oligopaint probes for TAD1 and TAD2 depicted as green and magenta bars. Interdomain interactions are quantified by boxplot in wildtype and $Tcf7^{-/-}$ DPs (n=7221 genomic interactions; boxplot centre, median; box limits, upper (75th) and lower (25th) percentiles; whiskers, 1.5× interquartile range; points, outliers). Two sided Paired wilcoxon ranksum test was performed. TAD1 spans chr6:71163477-71432963 while TAD2 spans chr6:71440321-71825773 in mm10.

b. A representative image of Oligopaint FISH probes in wildtype and $Tcf7^{-/-}$ DPs with magnification of each allele. Scale bar for full cell is 5µm and for magnified allele 1 µm, nuclei are stained with DAPI (blue).

c. 3D rendering of TAD1 and TAD2 in wildtype and TCF-1 deficient single DP T cells. Zoomed view of one allele per cell is shown in 3 rotations of 90°, scale bar is 5µm. **d-e.** Cumulative distribution plot (left) and corresponding boxplot (right) of overlap volume (**d**) and distance (**e**) between TAD1 and TAD2 across 312 individual wildtype DPs and 367 individual *Tct7^{-/-}* DPs. Kolmogorov-Smirnov test *P*-values and two-sided Wilcoxon ranksum test *P*-values are shown for cumulative distribution plots and corresponding boxplots, respectively. Cells were pooled from two to three mice per genotype. Overlap volume was defined using a 3D segmentation strategy⁴⁸ across a minimum of 300 alleles per condition. The overlap volume of TAD1 and TAD2 per allele was normalized to the volume of TAD1 (**d**). Distance was measured between the centroids of each domain across individual alleles (**e**). Data are shown as boxplots (centre, median; box limits, upper (75th) and lower (25th) percentiles; whiskers, 1.5× interquartile range; points, outliers)

Fig. 6. TCF-1 promotes NIPBL recruitment to active enhancers to reconstruct genome organization

a,c. Heatmap depicting genomic regions where TCF-1 led to a loss (**a**) or a gain (**c**) on the binding events of these proteins in addition to deposition of H3K27ac in DN3s. A binding atlas of cohesin occupancy was created by combining SMC1 and NIPBL peaks across various conditions. DESeq2 was used to determine TCF-1 dependent set of peaks between wildtype and *Tcf*^{7–/–} cells. Heatmaps show +/– 3kb around peak center. Pubicly available TCF-1 ChIP-seq from thymocytes is used²⁵. H3K27Ac, NIPBL, and SMC1 ChIP-seq and ATAC-seq experiments were generated in DN3s.

b. Genome browser view at a cluster of interferon-induced transmembrane genes. Yellow highlight shows binding of TCF-1 at genomic loci where H3K27ac, SMC1, and NIPBL binding events were concordantly reduced in $Tcf7^{-/-}$ DN3s.

d. Genome browser view of a representative example locus, yellow highlight shows genomic loci where H3K27ac, SMC1, and NIPBL binding events were concordantly increased in $Tcf7^{-/-}$ DN3s.

e-f. Seq-logos demonstrating top motif enrichment based on Homer analysis of genomic regions in which occupancy of cohesin was lost (**e**) or gained (**f**) in $Tcf7^{-/-}$ DN3s compared to random background regions. *P* values are calculated using hypergenometric test. **g-h.** Local pileup of long-range interactions anchored at genomic regions described in (**a**) and (**c**) with lost (**g**) and gained (**h**) occupancy. Hi-C data in DN3s were used.

AntibodiesAnti-CTCFMilliporeCat# 07-729; RRID-AB_414965Anti-SMC1BehlylCat# A300 055A; RRID-AB_2192467Normal Rabbit IgGCSTCat# 22065; IRRD-AB_1031062Anti-TCF-1CSTCat# 22065; IRRD-AB_1131062Biota anti-mouse CD8a (S3-6.7)BiotagendCat# 100703, RRID-AB_312742Anti-TMPBLBethylA301-779A; RRID-AB_211232Histone H3 Antibody, UnconjugatedCSTCat# 110005; RRID-AB_313563PE anti-mouse CD8 (S3-6.7)BioLegendCat# 110005; RRID-AB_312760PC anti-mouse CD4 (RM4-4)BioLegendCat# 110005; RRID-AB_312864Brilliant Violer 768" anti-mouse ICD2 (CG1)BioLegendCat# 10015; RRID-AB_312864Brilliant Violer 768" anti-mouse ICD2 (CG1)BioLegendCat# 10304; RRID-AB_31390BioLegendCat# 10304; RRID-AB_31390BioLegendCat# 108403; RRID-AB_31390Biota anti-mouse Ly-6GLy-6C (Gr-1) (RB-8C5)BioLegendCat# 10303, RRD-AB_31298Biota anti-mouse P20 (RA 562)BioLegendCat# 10203, RRD-AB_31298Biota anti-mouse P20 (RA 562)BioLegendCat# 10303, RRD-AB_31298Anti-rabit IgG, HRP-linked AntibodyCSTCat# 11603, RRID-AB_31298Ant	REAGENT or RESOURCE	SOURCE	IDENTIFIER
Ani-CTCFMilliporeCaff 07-729; RRID-AB_414965Anri-SCF1Caff 07-729; RRID-AB_2192467Normal Rabbit IgGCSTCaff 4279; RRID-AB_2192467Anri-TCF-1CSTCaff 4279; RRID-AB_101062Biolin anti-mouse CD8a (53.6.7)BioLegendCaff 100703, RRID-AB_312742Anti-TDF1BethylA301-779A; RRID-AB_211232Histone H3 (acetyl K27) antibodyAbcanab4729; RRID-AB_2118291Anti-Histone H3 (acetyl K27) antibodyAbcanab4729; RRID-AB_31563PE anti-mouse CD4 (SM-4-)BioLegendCaff 10071; RRID-AB_312750PE anti-mouse CD4 (SM-4-)BioLegendCaff 10015; RRID-AB_312864Bridina mi-mouse CD5 (CfG-1)BioLegendCaff 10015; RRID-AB_312864Bridin anti-mouse CD5 (CfG-1) (RB6-SC5)BioLegendCaff 10031; RRID-AB_31380Bioin anti-mouse Ly-GGLy-GC (Gr-1) (RB6-SC5)BioLegendCaff 1003; RRID-AB_313804Bioin anti-mouse Ly-GGLy-GC (Gr-1) (RB6-SC5)BioLegendCaff 10030; RRID-AB_313704Bioin anti-mouse CD1 (M17/0)BioLegendCaff 10203; RRID-AB_313704Bioin anti-mouse Ly-GGLy-GC (Gr-1) (RB6-SC5)BioLegendCaff 10203, RRID-AB_313704Bioin anti-mouse CD1 (M17/0)BioLegendCaff 10203, RRID-AB_313704Bioin anti-mouse D20 (AA3-682)BioLegendCaff 10203, RRID-AB_313704Bioin anti-mouse D20 (AA3-682)BioLegendCaff 10203, RRID-AB_313704Bioin anti-mouse D20 (AA3-682)Caff 10020; RRID-AB_313704Bioin anti-mouse D20 (AA3-682)Caff 10020; RRID-AB_313704Bioin anti-mouse D20 (AA3-682)Caff 10	Antibodies	•	•
Anti-SMC1BethylCar# A30-055A; RRID-AB_1031062Normal Rabbi IgGCSTCar# 2229; RRID-AB_1031062Anti-TCF-1CSTCar# 2209; RRID-AB_10320Biotin anti-mouse CD8a (53-6.7)BioLegendCar# 010703, RRID-AB_112122Histone H3 (acetyl K27) antibodyAbcamaM129; RRID-AB_2118291Anti-Thibione H2 Antibody, UnconjugatedCSTCar# 01071; RRID-AB_313663PE anti-mouse CD4 (RM-4)BioLegendCar# 11005; RRID-AB_313663PE anti-mouse CD4 (S4-6.7)BioLegendCar# 10071; RRID-AB_313664PCyT anti-mouse CD25 (PC61)BioLegendCar# 10015; RRID-AB_313264Billiant Violet 785 ^{er/*} anti-mouse/human CD44 (IM7)BioLegendCar# 10030; RRID-AB_313368Biolin anti-mouse Ly-GGLy-GC (Gr-1) (RB6-SCS)BioLegendCar# 10803; RRID-AB_313368Biotin anti-mouse CD116 (N170)BioLegendCar# 10803; RRID-AB_313368Biotin anti-mouse CD116 (N170)BioLegendCar# 10030; RRID-AB_313368Biotin anti-mouse CD116 (N170)BioLegendCar# 10203; RRID-AB_313764Biotin anti-mouse CD116 (N170)BioLegendCar# 10203; RRID-AB_313784Biotin anti-mouse CD116 (N170)BioLegendCar# 10203; RRID-AB_2099233Anti-totice CD116 (N170)BioLegendCar# 10203; RRID-AB_2099233Anti-totice RD20 (RA3-6B2)BioLegendCar#	Anti-CTCF	Millipore	Cat# 07-729; RRID:AB_441965
Normal Rabbit IgGCSTCatt # 2729; RRID:AB_1031062Ani:-TCF-1CSTCatt # 20208; RRID:AB_2199300Biotn anti-mouse CD8 (53.6.7)BioLegendCatt # 10070; RRID:AB_21122Anti-NIPBLAbbarnAbbarnAb30-7794; RRID:AB_211221Anti-Histone H3 Antibody, UnconjugatedCSTCatt # 7079; RRID:AB_311563PE anti-mouse CD4 (RM4.4)BioLegendCatt # 10005; RRID:AB_3112801APC anti-mouse CD5 (S5.6.7)BioLegendCatt # 10011; RRID:AB_312864PetGy anti-mouse CD5 (PG61)BioLegendCatt # 10011; RRID:AB_312864Brillant Volet 78.5" anti-mouse CD5 (Gr-1) (RB6-8CS)BioLegendCatt # 10304; RRID:AB_313808Botin anti-mouse LY-GCLy-G (Gr-1) (RB6-8CS)BioLegendCatt # 10304; RRID:AB_313704BioLegendCatt # 1020; RRID:AB_313704BioLegendCatt # 1020; RRID:AB_313704BioLegendCatt # 1020; RRID:AB_313704BioLegendCatt # 1020; RRID:AB_313704Biotin anti-mouse LY-GCLy-G (Gr-1) (RB6-8CS)BioLegendCatt # 1020; RRID:AB_313704Biotin anti-mouse CD1 Ib (M170)BioLegendCatt # 1020; RRID:AB_313704Biotin anti-mouse B220 (RA3-6B2)BioLegendCatt # 1020; RRID:AB_313704Biotin anti-mouse B220 (RA3-6B2)BioLegendCatt # 1020; RRID:AB_313704Biotin anti-mouse B220 (RA3-6B2)BioLegendCatt # 10403; RRID:AB_313704Biotin anti-mouse B220 (RA3-6B2)Catt # 1020; RRID:AB_313704Biotin anti-mouse B220 (RA3-6B2)Catt # 10403; RRID:AB_313704Biotin anti-mouse B220 (RA3-6B2)Catt # 10403; RRID:AB_313704Bioti	Anti-SMC1	Bethyl	Cat# A300-055A; RRID:AB_2192467
Anti-TCF-1CSTCat# 2206S; RRID: AB_2199300Biotin anti-mouse CD8a (53-6.7)BioLegendCat# 100703, RRID: AB_312742Anti-Misone H3 (acetyl K27) antibodyAbcamab4729; RRID: AB_1211232Histone H3 (acetyl K27) antibodyAbcamcSTCat# 9715, RRID: AB_311563PE anti-mouse CD4 (RM4-4)BioLegendCat# 116005; RRID: AB_312503PC anti-mouse CD5 (S3-6.7)BioLegendCat# 102015; RRID: AB_312864Brilliant Violet 785 th anti-mouse CD4 (RM7)BioLegendCat# 102015; RRID: AB_312864Brilliant Violet 785 th anti-mouse Ly-66/Ly-6C (Gr-1) (RB6-8C5)BioLegendCat# 103041; RRID: AB_313800Biotin anti-mouse Ly-66/Ly-6C (Gr-1) (RB6-8C5)BioLegendCat# 10304; RRID: AB_31390Biotin anti-mouse Ly-66/Ly-6C (Gr-1) (RB6-8C5)BioLegendCat# 10203, RRID: AB_31390Biotin anti-mouse V116 (M1/70)BioLegendCat# 10203, RRID: AB_31390Biotin anti-mouse V116 (M1/70)BioLegendCat# 10203, RRID: AB_31390Biotin anti-mouse V116 (M1/70)BioLegendCat# 10203, RRID: AB_31298Anti-abbi IgG, HRP-linked AntibodyCSTCat# 10203, RRID: AB_31298Anti-abbi IgG, HRP-linked AntibodyCSTCat# 10203, RRID: AB_31298Biotin anti-mouse B20 (RA3-6B2)BioLegendCat# 10737, RRID: AB_31298Anti-abbi IgG, HRP-linked AntibodyCSTCat# 10303, RRID: AB_31298Anti-abbi IgG, HRP-linked AntibodyCSTCat# 10303, RRID: AB_31298Biotin anti-mouse B20 (RA3-6B2)GitaCat# 10303, RRID: AB_31298Biotin anti-mouse B20 (RA3-6B2)Gita	Normal Rabbit IgG	CST	Cat# #2729; RRID:AB_1031062
Biolin anti-mouse CD8a (S3-6.7)BioLegendCat# 100703, RRID:AB_312742Anti-NIPBLBethylA301-779A; RRID:AB_1211232Histone H3 (acetyl K27) antibodyAbcamabd729, RRID:AB_211232Anti-Histone H3 Antibody, UnconjugatedCSTCat# 91705, RRID:AB_313630PE anti-mouse CD4 (RM4-4)BioLegendCat# 110057, RRID:AB_313690APC anti-mouse CD5 (S3-6.7)BioLegendCat# 100711, RRID:AB_312864Brilliant Violet 785 ^{1%} anti-mouse-human CD44 (IM7)BioLegendCat# 103041; RRID:AB_313680Brilliant Violet 785 ^{1%} anti-mouse-human CD44 (IM7)BioLegendCat# 10203, RRID:AB_313630Biotin anti-mouse Ly-GG1, CGr-1 (RB6-8C5)BioLegendCat# 108403; RRID:AB_31368Biotin anti-mouse NK1.1 (PK136)BioLegendCat# 10203, RRID:AB_313704Biotin anti-mouse NK1.1 (PK136)BioLegendCat# 10203, RRID:AB_313704Biotin anti-mouse RVK1.1 (PK136)BioLegendCat# 10203, RRID:AB_313704Biotin anti-mouse B20 (RA3-6B2)BioLegendCat# 10203, RRID:AB_312986Anti-rabbit IgG, HRP-linked AntibodyCSTCat# 01203, RRID:AB_31298Chenicalsy perfides, and recombinant proteinsThermoCat# 116203, RRID:AB_31298Dubecco's Modified Eagle Medium (DMEM)ThermoCat# 116305FBS (HyClone)CytivaCat# 11630070Parti-B40 mediumina CD4ThermoCat# 11630070Phicmine 200 mMInoraCat# 11630070Phicmine S00 mMInvitrogenCat# 1130070Phicmine S00 mMInvitrogenCat# 1130070Phicmine S00 mM <t< td=""><td>Anti-TCF-1</td><td>CST</td><td>Cat# 2206S; RRID:AB_2199300</td></t<>	Anti-TCF-1	CST	Cat# 2206S; RRID:AB_2199300
Ani-NIPBLBethylA301-779A; RRID-AB_1211232Histone H3 (acetyl K27) antibodyAbcamab4729; RRID-AB_2118291Anti-Histone H3 Antibody, UnconjugatedCSTCat# 91600; RRD-AB_313690PE anti-mouse CD4 (RM-4)BioLegendCat# 1000; RRD-AB_312780PC57 anti-mouse CD5 (S7-67)BioLegendCat# 102015; RRD-AB_312780PC57 anti-mouse CD25 (PC61)BioLegendCat# 10301; RRD-AB_312864Brilliant Violet 785 th anti-mouse human CD44 (IM7)BioLegendCat# 103041; RRD-AB_313368Biotin anti-mouse Ly-6G/Ly-CC (Gr-1) (RB6-8C5)BioLegendCat# 108403; RRD-AB_313368Biotin anti-mouse Vy-6G/Ly-CC (Gr-1) (RB6-8C5)BioLegendCat# 10203; RRD-AB_313786Biotin anti-mouse NL1.1 (PK136)BioLegendCat# 10203; RRD-AB_313786Biotin anti-mouse TP119 (TER-119)BioLegendCat# 10203; RRD-AB_313786Biotin anti-mouse S220 (RA3-662)BioLegendCat# 10203; RRD-AB_312786Anti-rabbit IgG, HRP-Inked AntibodyCSTCat# 0773730Centrology S20 (Cath S105)Cat# 10203; RRD-AB_31298Anti-rabbit IgG, HRP-Inked AntibodyCSTCat# 173730Chemically Competent E. coliThermoCat# 1737303Chemically Competent E. coliThermoCat# 1187305L-Ghatmine 200 mMInvitrogenCat# 1187305L-Ghatmine 200 mMInvitrogenCat# 1187305L-Ghatmine 200 mMInvitrogenCat# 1187305L-Ghatmine 200 mMInvitrogenCat# 11870070Pericellin StreptomycinGiboCat# 11870070Penicillin Strep	Biotin anti-mouse CD8a (53-6.7)	BioLegend	Cat# 100703, RRID:AB_312742
Histone H3 (acetyl K27) antibodyAbcamabd729; RRID:AB_211829/1Anti-Histone H3 Antibody, UnconjugatedCSTCa# 9715, RRID:AB_331563PE anti-mouse CD4 (RM-4)BioLegendCa# 110005; RRID:AB_313690APC anti-mouse CD8 (S3-67)BioLegendCa# 100711; RRID:AB_312750PeCy7 anti-mouse CD2 (PC61)BioLegendCa# 103015; RRID:AB_312864Brilliant Violet 785 th anti-mouse.human CD44 (IM7)BioLegendCa# 103041; RRID:AB_312864Brilliant Violet 785 th anti-mouse Ly-6G/Ly-6C (Gr-1) (RB6-8C5)BioLegendCa# 10803; RRID:AB_313368Biotin anti-mouse Ly-6G/Ly-6C (Gr-1) (RB6-8C5)BioLegendCa# 101203, RRID:AB_313764Biotin anti-mouse Ly-6G/Ly-6C (Gr-1) (RB6-8C5)BioLegendCa# 101203, RRID:AB_313768Biotin anti-mouse Ly-6G/Ly-6C (Gr-1) (RB6-8C5)BioLegendCa# 101203, RRID:AB_313704Biotin anti-mouse Ly-6G/Ly-6C (Gr-1) (RB6-8C5)BioLegendCa# 101203, RRID:AB_312786Biotin anti-mouse D211b (M1/70)BioLegendCa# 10203, RRID:AB_313704Biotin anti-mouse B220 (RA3-6B2)BioLegendCa# 10203, RRID:AB_312786Biotin anti-mouse B220 (RA3-6B2)BioLegendCa# 10203, RRID:AB_31298Anti-rabbi IgG, HRP-linked AntibodyCSTCa# 0777303Datecrial and Virus StrainsCa# 10773, RRID:AB_31298One Shot Sub3 Chemically Competent E. coliThermoCa# 11965084Pater and Virus StrainsCumCa# 10203Dubecco's Modified Eagle Medium (DMEM)ThermoCa# 11965084FBS (HyClone)CytivaCa# 1187085Lofutamine 200 mM <td< td=""><td>Anti-NIPBL</td><td>Bethyl</td><td>A301-779A; RRID:AB_1211232</td></td<>	Anti-NIPBL	Bethyl	A301-779A; RRID:AB_1211232
Anti-Histone H3 Antibody, UnconjugatedCSTCat# 9715, RRID:AB_31363PE anti-mouse CD4 (RM4-4)BioLegendCat# 116005; RRID:AB_313690APC anti-mouse CD8 (53-67)BioLegendCat# 100711; RRID:AB_312750Pe(57) anti-mouse CD5 (PC61)BioLegendCat# 103015; RRID:AB_312864Brilliant Violet 785" anti-mouse/human CD44 (IM7)BioLegendCat# 08207Biotin anti-mouse Ly-6G (Gr-1) (RB6-8C5)BioLegendCat# 08403; RRID:AB_31380Biotin anti-mouse Ly-6G (Gr-1) (RB6-8C5)BioLegendCat# 10403; RRID:AB_313704Biotin anti-mouse NK1.1 (PK136)BioLegendCat# 10123, RRID:AB_313704Biotin anti-mouse NK1.1 (PK136)BioLegendCat# 10203, RRID:AB_313704Biotin anti-mouse SC11b (M1/70)BioLegendCat# 10203, RRID:AB_313704Biotin anti-mouse B220 (RA3-6B2)BioLegendCat# 10203, RRID:AB_312988Anti-rabbit IgG, HRP-linked AntibodyCSTCat# 7074, RRID:AB_31298Destori Stol3 Chemically Competent E. coliThermoCat# 10303, RRID:AB_31298Dati-rabbit IgG, HRP-linked AntibodyCSTCat# 104050Dubeco's Modified Eagle Medium (DMEM)ThermoCat# 1160584FBS (HyClone)CytivaCat# 1160584BiolegendCat# 11603, Cat# 11603, Cat# 11603Bovine Serum, hat inactivatedThermoCat# 1167035RPMI 1640 mediumInvitrogenCat# 1167035L-Glutamine 200 mMLonzaCat# 116050Sodium Pyruvate (100 mM)InvitrogenCat# 1160070Penicillin. StreptomycinGibcoCat# 11360070 <td>Histone H3 (acetyl K27) antibody</td> <td>Abcam</td> <td>ab4729; RRID:AB_2118291</td>	Histone H3 (acetyl K27) antibody	Abcam	ab4729; RRID:AB_2118291
PE anti-mouse CD4 (RM4-4)BioLegendCat# 116005; RRID: AB_313690APC anti-mouse CD8 (33-6.7)BioLegendCat# 100711; RRID: AB_312750PcCy7 anti-mouse CD25 (PC61)BioLegendCat# 102015; RRID: AB_312864Brilliant Violer 785 ¹⁴ anti-mouse/human CD44 (IM7)BioLegendCat# 103041; RRID: AB_312864APC StreptavidinBioLegendCat# 103041; RRID: AB_11218802APC StreptavidinBioLegendCat# 108403; RRID: AB_313368Biotin anti-mouse Ly-6G/Ly-6C (Gr-1) (RB6-8C5)BioLegendCat# 108703; RRID: AB_313390Biotin anti-mouse CD11b (M170)BioLegendCat# 108703; RRID: AB_313704Biotin anti-mouse CD11b (M170)BioLegendCat# 10303; RRID: AB_313704Biotin anti-mouse CD11b (M170)BioLegendCat# 10303; RRID: AB_312786Biotin anti-mouse B220 (RA3-6B2)BioLegendCat# 10303; RRID: AB_312786Datior Sth3 Chemically Competent E. coliThernoCat# 7074, RRID: AB_2092233Chemicals, peptides, and recombinant proteinsDottor Sth3 Chemically Competent E. coliThernoDathecco's Modified Eagle Medium (DMEM)ThernoCat# 11965084FBS (HyClone)CytivaCat# 11875085L-Glutanine 200 mMLonzaCat# 1136070Pericillin-StreptomycinGibcoCat# 1140050Sodium Pyrovate (100 mM)InvitrogenCat# 1140050Sodium Pyrovate (100 mM)InvitrogenCat# 1140050Sodium Pyrovate (100 mM)InvitrogenCat# 1140050Sodium Pyrovate (100 mM)FibernoCat# 1179102Gateway Chonase II LR	Anti-Histone H3 Antibody, Unconjugated	CST	Cat# 9715, RRID:AB_331563
APC anti-mouse CD8 (53-6.7)BioLegendCat# 100711; RRD:AB_312750PcCy7 anti-mouse CD25 (PC61)BioLegendCat# 102015; RRD:AB_312864Brilliant Violet 785 [™] anti-mouse/human CD44 (IM7)BioLegendCat# 103041; RRD:AB_11218802APC StreptavidinBioLegendCat# 405207Biotin anti-mouse Ly-GGLy-GC (Gr-1) (RB6-8C5)BioLegendCat# 108403; RRD:AB_31368Biotin anti-mouse NK1.1 (PK136)BioLegendCat# 108703; RRD:AB_313704Biotin anti-mouse Ter119 (TER-119)BioLegendCat# 10203, RRD:AB_313704Biotin anti-mouse B220 (RA3-6B2)BioLegendCat# 103203, RRD:AB_312988Anti-rabbit IgG, HRP-linked AntibodyCSTCat# 7074, RRD:AB_31298Anti-rabbit IgG, HRP-linked AntibodyCSTCat# 7074, RRD:AB_31298Doe Shot Stbl3 Chemically Competent E. coliThermoCat# 717303Chemicals, peptides, and recombinant proteinsCytivaCat# 513005Dulbecco's Modified Eagle Medium (DMEM)ThermoCat# 11965084FBS (HyClone)CytivaCat# 11965084FBS (HyClone)CytivaCat# 1185085L-Glutamine 200 mMLonzaCat# 1187085L-Glutamine 200 mMLonzaCat# 1140050Sodium Pyruvate (100 mM)InvitrogenCat# 1140050Gateway Clonase II LRThermoCat# 1140050Gateway Clonase II LRThermoCat# 1178020PolybreneSigmaCat# 1178020PolybreneSigmaCat# 2311ChloroquineSigmaCat# 2311	PE anti-mouse CD4 (RM4-4)	BioLegend	Cat# 116005; RRID:AB_313690
Pecy7 anti-mouse CD25 (PC61)BioLegendCat# 102015; RRID:AB_312864Brilliant Violet 785 ⁷⁴ anti-mouse/human CD44 (IM7)BioLegendCat# 103041; RRID:AB_11218802APC StreptavidinBioLegendCat# 405207Biotin anti-mouse Ly-6G/Ly-6C (Gr-1) (RB6-8C5)BioLegendCat# 108403; RRID:AB_313368Biotin anti-mouse NK1.1 (PK136)BioLegendCat# 108703; RRID:AB_313704Biotin anti-mouse CD11b (M1/70)BioLegendCat# 101203, RRID:AB_312786Biotin anti-mouse CD11b (M1/70)BioLegendCat# 101203, RRID:AB_312786Biotin anti-mouse CD11b (M1/70)BioLegendCat# 103203, RRID:AB_312786Biotin anti-mouse B220 (RA3-6B2)BioLegendCat# 103203, RRID:AB_312988Anti-rabbit IgG, HRP-linked AntibodyCSTCat# 7074, RRID:AB_312988Anti-rabbit IgG, HRP-linked AntibodyCSTCat# 7074, RRID:AB_312988Dubecco's Modified Eagle Medium (DMEM)ThermoCat# 737303Chemicals, peptides, and recombinant proteinsCut# 26170035Dulbecco's Modified Eagle Medium (DMEM)ThermoCat# 11965084FBS (HyClone)CytivaCat# 11965084FBS (HyClone)CytivaCat# 11875085L-Glutamine 200 mMLonzaCat# 11875085L-Glutamine 200 mMLonzaCat# 1140050Sodium Pyruvate (100 mM)InvitrogenCat# 1140050Sodium Pyruvate (100 mM)InvitrogenCat# 1140050Gateway Clonase II LRThermoCat# 11780020PolybreneSigmaCat# 11780020PolybreneSigmaCat# 12311 <td>APC anti-mouse CD8 (53-6.7)</td> <td>BioLegend</td> <td>Cat# 100711; RRID:AB_312750</td>	APC anti-mouse CD8 (53-6.7)	BioLegend	Cat# 100711; RRID:AB_312750
Brilliant Violet 785 ¹¹⁴ anti-mouse/human CD-44 (IM7)BioLegendCa# 03041; RRID:AB_11218802APC StreptavidinBioLegendCat# 405207Biotin anti-mouse Ly-6G/Ly-6C (Gr-1) (RB6-8C5)BioLegendCat# 108403; RRID:AB_313368Biotin anti-mouse NK1.1 (PK136)BioLegendCat# 108703; RRID:AB_313390Biotin anti-mouse CD11b (M1/70)BioLegendCat# 101203, RRID:AB_312786Biotin anti-mouse Ter119 (TER-119)BioLegendCat# 10203, RRID:AB_313704Biotin anti-mouse B220 (RA3-6B2)BioLegendCat# 103203, RRID:AB_313704Biotin anti-mouse B220 (RA3-6B2)BioLegendCat# 103203, RRID:AB_312988Anti-rabbit IgG, HRP-linked AntibodyCSTCat# 7074, RRID:AB_2099233Bacterial and Yirus StrainsDubeco's Modified Eagle Medium (DMEM)ThermoCat# C737303Chemicals, peptides, and recombinant proteinsDubeco's Modified Eagle Medium (DMEM)ThermoCat# 11965084FBS (HyClone)CytivaCat# 8H30910.03Bovine Serum, heat inactivatedThermoCat# 11875085L-Glutamine 200 mMLonzaCat# 117605EMEM Non-Essential Annio Acids Solution (100X)InvitrogenCat# 1140050Sodium Pyruvate (100 mM)InvitrogenCat# 11140050Cat# 11140050Solution 11470050Gateway Clonase II LRThermoCat# 1179020Cat# 1179020Gateway Clonase II LRThermoCat# 1179020Gateway Clonase II LRThermoCat# 1179020PolybreneSigmaCat# 1179030ThermoCat# 1179030Gateway Clonase II LRCohoroquineCat	PeCy7 anti-mouse CD25 (PC61)	BioLegend	Cat# 102015; RRID:AB_312864
APC StreptavidinBioLegendCat# 405207Biotin anti-mouse Ly-6G/Ly-6C (Gr-1) (RB6-8C5)BioLegendCat# 108403; RRID:AB_313368Biotin anti-mouse NK1.1 (PK136)BioLegendCat# 108703; RRID:AB_313390Biotin anti-mouse CD11b (M1/70)BioLegendCat# 10203, RRID:AB_313704Biotin anti-mouse Ter119 (TER-119)BioLegendCat# 116203, RRID:AB_313704Biotin anti-mouse B220 (RA3-6B2)BioLegendCat# 103203, RRID:AB_313704Biotin anti-mouse B220 (RA3-6B2)BioLegendCat# 103203, RRID:AB_312988Anti-rabbit IgG, HRP-linked AntibodyCSTCat# 0774, RRID:AB_312988Doe Shot Sth3 Chemically Competent E. coliThermoCat# 077303Chemicals, peptides, and recombinant proteinsDulbcco's Modified Eagle Medium (DMEM)ThermoDulbcco's Modified Eagle Medium (DMEM)ThermoCat# 11965084FBS (HyClone)CytivaCat# 11965084Bovin Serum, heat inactivatedThermoCat# 26170035RPMI 1640 mediumInvitrogenCat# 1187085L-Glutamine 200 mMLonzaCat# 114050Sodium Pyruvate (100 mM)InvitrogenCat# 1140050Sodium Pyruvate (100 mM)InvitrogenCat# 11360070Penicillin-StreptomycinGibboCat# 1179002Gateway Clonase II LRThermoCat# 1179020FolybreeSigmaCat# 1178020PolybreeSigmaCat# 117803-GLipofectanine 3000ThermoCat# 1129Fuegene HDPromegaCat# 62311ChoroquineSigmaCat# C62	Brilliant Violet 785 [™] anti-mouse/human CD44 (IM7)	BioLegend	Cat# 103041; RRID:AB_11218802
Biotin anti-mouse Ly-6G/Ly-6C (Gr-1) (RB6-8C5)BioLegendCat# 108403; RRID:AB_313368Biotin anti-mouse NK1.1 (PK136)BioLegendCat# 108703; RRID:AB_313390Biotin anti-mouse CD11b (M1/70)BioLegendCat# 116203, RRID:AB_312786Biotin anti-mouse Ter119 (TER-119)BioLegendCat# 116203, RRID:AB_313704Biotin anti-mouse B220 (RA3-6B2)BioLegendCat# 103203, RRID:AB_312988Anti-rabbit IgG, HRP-linked AntibodyCSTCat# 7074, RRID:AB_2099233Pacterial and Virus StrainsOne Shot Skb13 Chemically Competent E. coliThermoCat# C737303Chemicals, peptides, and recombinant proteinsDulbecco's Modified Eagle Medium (DMEM)ThermoCat# 11965084FBS (HyClone)CytivaCat# 11965084FBS (HyClone)CytivaCat# 11875085L-Glutamine 200 mMInvitrogenCat# 1140050MEM Non-Essential Amino Acids Solution (100X)InvitrogenCat# 11360070Penicillin-StreptomycinGibcoCat# 1140050Sodium Pyruvate (100 mM)InvitrogenCat# 11360070Penicillin-StreptomycinGibcoCat# 11791020Gateway Clonase II LRThermoCat# 11791020Gateway Clonase II BPThermoCat# 1179020PolybreneSigmaCat# 12300008Fugene HDPromegaCat# 2311ChloroquineSigmaCat# 6628-25G	APC Streptavidin	BioLegend	Cat# 405207
Biotin anti-mouse NK1.1 (PK136)BioLegendCat# 108703; RRID:AB_313390Biotin anti-mouse CD11b (M1/70)BioLegendCat# 101203, RRID:AB_312786Biotin anti-mouse Ter119 (TER-119)BioLegendCat# 116203, RRID:AB_313704Biotin anti-mouse B220 (RA3-6B2)BioLegendCat# 103203, RRID:AB_312988Anti-rabbit IgG, HRP-linked AntibodyCSTCat# 7074, RRID:AB_2099233Bacterial and Virus StrainsThermoCat# C737303One Shot Stbl3 Chemically Competent E. coliThermoCat# C737303Chemicals, peptides, and recombinant proteinsDulbecco's Modified Eagle Medium (DMEM)ThermoDubecco's Modified Eagle Medium (DMEM)ThermoCat# 11965084FBS (HyClone)CytivaCat# 11875085L-Glutamine 200 mMLonzaCat# 11875085L-Glutamine 200 mMInvitrogenCat# 1140050Sodium Pyruvate (100 mM)InvitrogenCat# 11140050Sodium Pyruvate (100 mM)InvitrogenCat# 11791020Gateway Clonase II LRThermoCat# 11791020Gateway Clonase II LRThermoCat# 11791020FolybreneSigmaCat# 11791020Fugene HDPromegaCat# 2311ChloroquineSigmaCat# 2311ChloroquineSigmaCat# 2311	Biotin anti-mouse Ly-6G/Ly-6C (Gr-1) (RB6-8C5)	BioLegend	Cat# 108403; RRID:AB_313368
Biotin anti-mouse CD11b (M1/70)BioLegendCat# 101203, RRID:AB_312786Biotin anti-mouse Ter119 (TER-119)BioLegendCat# 116203, RRID:AB_313704Biotin anti-mouse B220 (RA3-6B2)BioLegendCat# 103203, RRID:AB_312988Anti-rabbit IgG, HRP-linked AntibodyCSTCat# 7074, RRID:AB_2099233Bacterial and Virus StrainsOne Shot Stbl3 Chemically Competent E. coliThermoCat# C737303Chemicals, peptides, and recombinant proteinsDulbecco's Modified Eagle Medium (DMEM)ThermoCat# 11965084FBS (HyClone)CytivaCat# SH30910.03Bovine Serum, heat inactivatedThermoCat# 26170035RPMI 1640 mediumInvitrogenCat# 11875085L-Glutamine 200 mMLonzaCat# 1140050Sodium Pyruvate (100 mM)InvitrogenCat# 11360070Penicillin-StreptomycinGibcoCat# 11791020Gateway Clonase II LRThermoCat# 1179020PolybreneSigmaCat# TR-1003-GLipofectamine 3000ThermoCat# 2311ChloroquineSigmaCat# 2231	Biotin anti-mouse NK1.1 (PK136)	BioLegend	Cat# 108703; RRID:AB_313390
Biotin anti-mouse Ter119 (TER-119)BioLegendCat# 116203, RRID:AB_313704Biotin anti-mouse B220 (RA3-GB2)BioLegendCat# 103203, RRID:AB_312988Anti-rabbit IgG, HRP-linked AntibodyCSTCat# 7074, RRID:AB_3099233Bacterial and Virus StrainsOne Shot Stbl3 Chemically Competent E. coliThermoCat# C737303Chemicals, peptides, and recombinant proteinsDulbecco's Modified Eagle Medium (DMEM)ThermoCat# 11965084FBS (HyClone)CytivaCat# 8H30910.03Bovine Serum, heat inactivatedThermoCat# 26170035RPMI 1640 mediumInvitrogenCat# 11875085L-Glutamine 200 mMLonzaCat# 1140050Sodium Pyruvate (100 mM)InvitrogenCat# 1140050Sodium Pyruvate (100 mM)GibcoCat# 1140020Penicillin-StreptomycinGibcoCat# 11479020Gateway Clonase II LRThermoCat# 11719020PolybreneSigmaCat# R-1003-GLipofectamine 3000ThermoCat# 2311ChloroquineSigmaCat# 2211ChoroquineSigmaCat# 2211	Biotin anti-mouse CD11b (M1/70)	BioLegend	Cat# 101203, RRID:AB_312786
Biotin anti-mouse B220 (RA3-6B2)BioLegendCat# 103203, RRID:AB_312988Anti-rabbit IgG, HRP-linked AntibodyCSTCat# 7074, RRID:AB_2099233Bacterial and Virus StrainsOne Shot Stbl3 Chemically Competent E. coliThermoCat# C737303Chemicals, peptides, and recombinant proteinsDulbecco's Modified Eagle Medium (DMEM)ThermoCat# 11965084FBS (HyClone)CytivaCat# SH30910.03Bovine Serum, heat inactivatedThermoCat# 26170035RPMI 1640 mediumInvitrogenCat# 11875085L-Glutamine 200 mMLonzaCat# 1140050Sodium Pyruvate (100 mM)InvitrogenCat# 11360070Penicillin-StreptomycinGibcoCat# 11360070Gateway Clonase II LRThermoCat# 11791020Gateway Clonase II BPThermoCat# 11789020PolybreneSigmaCat# 1200008Fugene HDPromegaCat# 22311ChloroquineSigmaCat# 6628-25G	Biotin anti-mouse Ter119 (TER-119)	BioLegend	Cat# 116203, RRID:AB_313704
Anti-rabbit IgG, HRP-linked AntibodyCSTCat# 7074, RRID:AB_2099233Bacterial and Virus StrainsThermoCat# C737303One Shot Stbl3 Chemically Competent E. coliThermoCat# C737303Chemicals, peptides, and recombinant proteinsThermoCat# 11965084Dubecco's Modified Eagle Medium (DMEM)ThermoCat# SH30910.03FBS (HyClone)CytivaCat# 5H30910.03Bovine Serum, heat inactivatedThermoCat# 26170035RPMI 1640 mediumInvitrogenCat# 11875085L-Glutamine 200 mMLonzaCat# 117-605EMEM Non-Essential Amino Acids Solution (100X)InvitrogenCat# 1140050Sodium Pyruvate (100 mM)InvitrogenCat# 11360070Penicillin-StreptomycinGibcoCat# 115140122Gateway Clonase II LRThermoCat# 11791020Gateway Clonase II BPThermoCat# 11789020PolybreneSigmaCat# 12300008Fugene HDPromegaCat# E2311ChloroquineSigmaCat# C628-25G	Biotin anti-mouse B220 (RA3-6B2)	BioLegend	Cat# 103203, RRID:AB_312988
Bacterial and Virus StrainsOne Shot Stbl3 Chemically Competent E. coliThermoCat# C737303Chemicals, peptides, and recombinant proteinsDulbecco's Modified Eagle Medium (DMEM)ThermoCat# 11965084FBS (HyClone)CytivaCat# SH30910.03Bovine Serum, heat inactivatedThermoCat# 26170035RPMI 1640 mediumInvitrogenCat# 11875085L-Glutamine 200 mMLonzaCat# 11140050Sodium Pyruvate (100 mM)InvitrogenCat# 11140050Sodium Pyruvate (100 mM)InvitrogenCat# 11360070Penicillin-StreptomycinGibcoCat# 11791020Gateway Clonase II LRThermoCat# 11791020PolybreneSigmaCat# TR-1003-GLipofectamine 3000ThermoCat# 2311ChloroquineSigmaCat# 628-25G	Anti-rabbit IgG, HRP-linked Antibody	CST	Cat# 7074, RRID:AB_2099233
One Shot Stbl3 Chemically Competent E. coliThermoCat# C737303Chemicals, peptides, and recombinant proteinsDulbecco's Modified Eagle Medium (DMEM)ThermoCat# 11965084FBS (HyClone)CytivaCat# SH30910.03Bovine Serum, heat inactivatedThermoCat# 26170035RPMI 1640 mediumInvitrogenCat# 11875085L-Glutamine 200 mMLonzaCat# 117-605EMEM Non-Essential Amino Acids Solution (100X)InvitrogenCat# 11140050Sodium Pyruvate (100 mM)InvitrogenCat# 11360070Penicillin-StreptomycinGibcoCat# 11791020Gateway Clonase II LRThermoCat# 1179020PolybreneSigmaCat# TR-1003-GLipofectamine 3000ThermoCat# 12300008Fugene HDPromegaCat# E2311ChloroquineSigmaCat# C6628-25G	Bacterial and Virus Strains		
Chemicals, peptides, and recombinant proteinsInclude Content of Catter Conten	One Shot Stbl3 Chemically Competent E. coli	Thermo	Cat# C737303
Dulbecco's Modified Eagle Medium (DMEM)ThermoCat# 11965084FBS (HyClone)CytivaCat# SH30910.03Bovine Serum, heat inactivatedThermoCat# 26170035RPMI 1640 mediumInvitrogenCat# 11875085L-Glutamine 200 mMLonzaCat# 117-605EMEM Non-Essential Amino Acids Solution (100X)InvitrogenCat# 1140050Sodium Pyruvate (100 mM)InvitrogenCat# 11360070Penicillin-StreptomycinGibcoCat# 15140122Gateway Clonase II LRThermoCat# 11791020Gateway Clonase II BPThermoCat# 11789020PolybreneSigmaCat# 12300008Lipofectamine 3000ThermoCat# L3000008Fugene HDPromegaCat# E2311ChloroquineSigmaCat# C628-25G	Chemicals, peptides, and recombinant proteins		
FBS (HyClone)CytivaCat# SH30910.03Bovine Serum, heat inactivatedThermoCat# 26170035RPMI 1640 mediumInvitrogenCat# 11875085L-Glutamine 200 mMLonzaCat# 117-605EMEM Non-Essential Amino Acids Solution (100X)InvitrogenCat# 1140050Sodium Pyruvate (100 mM)InvitrogenCat# 11360070Penicillin-StreptomycinGibcoCat# 115140122Gateway Clonase II LRThermoCat# 11789020Gateway Clonase II BPThermoCat# 11789020PolybreneSigmaCat# 12300008Lipofectamine 3000ThermoCat# L3000008Fugene HDPromegaCat# E2311ChloroquineSigmaCat# C6628-25G	Dulbecco's Modified Eagle Medium (DMEM)	Thermo	Cat# 11965084
Bovine Serum, heat inactivatedThermoCat# 26170035RPMI 1640 mediumInvitrogenCat# 11875085L-Glutamine 200 mMLonzaCat# 17-605EMEM Non-Essential Amino Acids Solution (100X)InvitrogenCat# 11140050Sodium Pyruvate (100 mM)InvitrogenCat# 11360070Penicillin-StreptomycinGibcoCat# 15140122Gateway Clonase II LRThermoCat# 11791020Gateway Clonase II BPThermoCat# 11789020PolybreneSigmaCat# TR-1003-GLipofectamine 3000ThermoCat# E2311Fugene HDPromegaCat# E2311ChloroquineSigmaCat# C6628-25G	FBS (HyClone)	Cytiva	Cat# SH30910.03
RPMI 1640 mediumInvitrogenCat# 11875085L-Glutamine 200 mMLonzaCat# 17-605EMEM Non-Essential Amino Acids Solution (100X)InvitrogenCat# 11140050Sodium Pyruvate (100 mM)InvitrogenCat# 11360070Penicillin-StreptomycinGibcoCat# 15140122Gateway Clonase II LRThermoCat# 11791020Gateway Clonase II BPThermoCat# 11789020PolybreneSigmaCat# TR-1003-GLipofectamine 3000ThermoCat# L3000008Fugene HDPromegaCat# E2311ChloroquineSigmaCat# C6628-25G	Bovine Serum, heat inactivated	Thermo	Cat# 26170035
L-Glutamine 200 mMLonzaCat# 17-605EMEM Non-Essential Amino Acids Solution (100X)InvitrogenCat# 11140050Sodium Pyruvate (100 mM)InvitrogenCat# 11360070Penicillin-StreptomycinGibcoCat# 15140122Gateway Clonase II LRThermoCat# 11791020Gateway Clonase II BPThermoCat# 11789020PolybreneSigmaCat# TR-1003-GLipofectamine 3000ThermoCat# L3000008Fugene HDPromegaCat# E2311ChloroquineSigmaCat# C6628-25G	RPMI 1640 medium	Invitrogen	Cat# 11875085
MEM Non-Essential Amino Acids Solution (100X)InvitrogenCat# 11140050Sodium Pyruvate (100 mM)InvitrogenCat# 11360070Penicillin-StreptomycinGibcoCat# 15140122Gateway Clonase II LRThermoCat# 11791020Gateway Clonase II BPThermoCat# 11789020PolybreneSigmaCat# TR-1003-GLipofectamine 3000ThermoCat# L3000008Fugene HDPromegaCat# E2311ChloroquineSigmaCat# C6628-25G	L-Glutamine 200 mM	Lonza	Cat# 17-605E
Sodium Pyruvate (100 mM)InvitrogenCat# 11360070Penicillin-StreptomycinGibcoCat# 15140122Gateway Clonase II LRThermoCat# 11791020Gateway Clonase II BPThermoCat# 11789020PolybreneSigmaCat# TR-1003-GLipofectamine 3000ThermoCat# L3000008Fugene HDPromegaCat# E2311ChloroquineSigmaCat# C6628-25G	MEM Non-Essential Amino Acids Solution (100X)	Invitrogen	Cat# 11140050
Penicillin-StreptomycinGibcoCat# 15140122Gateway Clonase II LRThermoCat# 11791020Gateway Clonase II BPThermoCat# 11789020PolybreneSigmaCat# TR-1003-GLipofectamine 3000ThermoCat# L3000008Fugene HDPromegaCat# E2311ChloroquineSigmaCat# C6628-25G	Sodium Pyruvate (100 mM)	Invitrogen	Cat# 11360070
Gateway Clonase II LRThermoCat# 11791020Gateway Clonase II BPThermoCat# 11789020PolybreneSigmaCat# TR-1003-GLipofectamine 3000ThermoCat# L3000008Fugene HDPromegaCat# E2311ChloroquineSigmaCat# C6628-25G	Penicillin-Streptomycin	Gibco	Cat# 15140122
Gateway Clonase II BPThermoCat# 11789020PolybreneSigmaCat# TR-1003-GLipofectamine 3000ThermoCat# L3000008Fugene HDPromegaCat# E2311ChloroquineSigmaCat# C6628-25G	Gateway Clonase II LR	Thermo	Cat# 11791020
PolybreneSigmaCat# TR-1003-GLipofectamine 3000ThermoCat# L3000008Fugene HDPromegaCat# E2311ChloroquineSigmaCat# C6628-25G	Gateway Clonase II BP	Thermo	Cat# 11789020
Lipofectamine 3000ThermoCat# L3000008Fugene HDPromegaCat# E2311ChloroquineSigmaCat# C6628-25G	Polybrene	Sigma	Cat# TR-1003-G
Fugene HDPromegaCat# E2311ChloroquineSigmaCat# C6628-25G	Lipofectamine 3000	Thermo	Cat# L3000008
Chloroquine Sigma Cat# C6628-25G	Fugene HD	Promega	Cat# E2311
	Chloroquine	Sigma	Cat# C6628-25G

REAGENT or RESOURCE	SOURCE	IDENTIFIER
G418	GIBCO	Cat# 11811-023
Doxycycline	Sigma	Cat# D9891
Dimethylformamide	Sigma-Aldrich	Cat# D4551
Puromycin	Takara	Cat# 631305
Ethylene glycol bis(succinic acid N hydroxysuccinimideester) (EGS)	Thermo	Cat# 21565
DMSO	Fisher	Cat# BP231-1
Formaldehyde solution 16%	Thermo	Cat# PI28908
Glycine	Thermo	Cat# 15527013
cOmplete, Mini, EDTA-free Protease Inhibitor Cocktail	Roche	Cat# 11836170001
MboI	NEB	Cat# R0147
Biotin-14-dATP	Invitrogen	Biotin-14-dATP
dCTP	Invitrogen	Cat# 18253-013
dTTP	Invitrogen	Cat# 18255-018
dGTP	Invitrogen	Cat# 18254-011
Tris HCl, pH 7.5, 1M	Thermo	Cat# 15567027
NaCl, 5M	Thermo	Cat# AM9759
MgCl2 1M	Thermo	Cat# AM9530G
IGEPAL CA-630	Sigma	Cat# I8896-50ML
EDTA	Invitrogen	Cat# 15575-038
Protein A Magnetic beads	Pierce	Cat# 88846
Lithium Chloride, 8M	Sigma-Aldrich	Cat# L7026
Sodium bicarbonate	Sigma-Aldrich	Cat#144-55-8
T4 DNA Ligase	NEB	Cat# M0202L
BSA, 50mg/mL	Invitrogen	Cat# AM2616
Tween 20	BIO-RAD	Cat# 170-6531
DNA Polymerase I, Large (Klenow) Fragment	NEB	Cat# M0210S
Qubit dsDNA HS Assay Kit	Invitrogen	Cat# Q32851
Dynabeads MyOne Streptavidin C-1	Invitrogen	Cat# 65001
Phusion PCR Master Mix	NEB	Cat# M0531
Nextera XT Index Kit	Illumina	Cat# FC-131-1001
SPRIselect	Beckman Coulter	Cat# B23318
MinElute Reaction Cleanup Kit	QIAGEN	Cat# 28204
QIAQuick PCR Purification Kit	QIAGEN	Cat# 28104
Phosphate-Buffered Saline, 1X	Thermo	Cat# 10010031
RNase	Thermo	Cat# EN0531
Proteinase K	Thermo	Cat# AM2546
Protein G Dynabeads	Thermo	Cat# 10003D
2-Mercaptoethanol	Thermo	Cat# 21985023
Buffer RLT Plus	QIAGEN	Cat# 1053393

REAGENT or RESOURCE	SOURCE	IDENTIFIER
RNeasy Plus Micro Kit	QIAGEN	Cat# 74034
Trypsin-EDTA (0.05%)	Gibco	Cat# 25300054
RIPA Buffer (10X)	CST	Cat# 9806
NuPAGE LDS Sample Buffer (4X)	Thermo	Cat# NP0007
NuPAGE [™] 4 to 12%, Bis-Tris, 1.0 mm, Mini Protein Gel, 10-well	Thermo	Cat# NP0321BOX
iBlot [™] 2 Transfer Stacks, nitrocellulose, mini	Thermo	Cat# IB23002
Tris Buffered Saline with Tween [®] 20	CST	Cat# 9997S
SuperSignal [™] West Femto Maximum Sensitivity Substrate	Thermo	Cat# 34095
Polysine adhesion glass slides	Electron Microscopy Sciences	Cat# 63412-01
Silicone Isolators	Electron Microscopy Sciences	Cat# 70339-05
Ethanol	Decon Laboratories	2716
Dimethylformamide	Sigma-Aldrich	Cat# D4551
Triton X-100	Sigma-Aldrich	Cat# T8787-250ML
Polyvinylsulfonic acid (PVSA)	Sigma-Aldrich	Cat# 278424
Fisherbrand [™] Premium Cover Glasses	Fisher Scientific	Cat# 12-548-5M
Nowrinkle rubber cement	Elmer's	Cat# 34633
Slowfade Gold Antifade Reagent	Invitrogen by Thermo Fisher Scientific	Cat# S36936
Secondary Oligopaint probe NDB_1279_Atto565: /5ATTO565N/ AGC GAA TCC GAC GCA CCG CTA /3ATTO565N/		
Secondary Oligopaint probe NDB_1281_Alexa647: /5Alex647N/ AGG ACC CTG TTC GGC TAA CCA /3AlexF647N/		
Dextran sulfate	Sigma Aldrich	Cat# D8906-50G
20X SSC buffer	Corning	Cat# 46-020-CM
Phosphate-Buffered Saline, 10X	Stemcell Technologies	Cat# 37354
Formamide, molecular grade	Promega	Cat# H5052
Formamide, > 99.5% (4 × 4L)	Sigma Aldrich	Cat# 221198-4X4L
dNTP mixture, 100mM (25mM of each)	Thomas Scientific	Cat# C788T68
RNase A, DNase and protease-free (10 mg/mL)	Thermo Fisher	Cat# EN0531
Defy & Inspire [™] clear nail polish	Target Corporation	Cat# 052-06-3573
Critical commercial assays		
Illumina Tagment DNA Enzyme and Buffer Large Kit	Illumina	Cat# 20034198
SMARTer [®] Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian	Takara	Cat# 634413
NEBNext Ultra II DNA Library Prep Kit for Illumina	NEB	Cat# E7645S
Arima HiC+ kit	Arima Genomics	
Accel-NGS 2S Plus DNA Library Kit	Swift Biosciences	Cat# 21024
2S SET A INDEXING KIT	Swift Biosciences	Cat# 26148
KAPA Library Amplification Kit with Primer Mix	Roche	KK2620
Kapa library Quantification kit	Roche	7960140001

REAGENT or RESOURCE	SOURCE	IDENTIFIER
D1000 ScreenTape	Agilent	Cat# 5067-5582
D1000 Reagents	Agilent	Cat# 5067-5583
High Sensitivity D1000 ScreenTape	Agilent	Cat# 5067-5584
High Sensitivity D1000 Reagents	Agilent	Cat# 5067-5585
Genomic DNA ScreenTape	Agilent	Cat# 5067-5365
Genomic DNA Reagents	Agilent	Cat# 5067-5366
RNA ScreenTape	Agilent	Cat# 5067-5576
RNA ScreenTape Ladder	Agilent	Cat# 5067-5578
RNA ScreenTape Sample Buffer	Agilent	Cat# 5067-5577
EasySep [™] Release Mouse Biotin Positive Selection Kit	Stemcell	Cat# 17655
EasySep [™] Mouse CD4 Positive Selection Kit II	Stemcell	Cat# 18952
Recombinant DNA		
Plasmid: pInducer20	Addgene	Cat# 44012; RRID:Addgene_44012
Plasmid: pSL21-vex	Addgene	Cat# 158230
Plasmid: MSCV-Cas9_Puro	Addgene	Cat# 65655
Plasmid: pCL-Eco	(Naviaux et al., 1996)	
Deposited data		I
HiC, HiChIP, ChIPseq, RNAseq	This study	GSE178348
Publicly accessible data		
TCF-1 ChIPseq in thymus	24	GSE46662
CTCF ChIPseq in DP T cells	27	GSE141853
SMC1 HiChIP in DP T cells	27	GSE141853
3e Hi-C during T cell development	25	GSE79422
Histone modifications during T cell development	29	GSE31235
ATAC-seq during T cell development	49	GSE100738
RNA-seq during T cell development	25	GSE79422
Mouse B cell hic	42	4DNFISA93XFU
Mouse cardiomyocyte hic	(Rosa-Garrido et al., 2017)	GSE96693
Mouse mESC hic	(Bonev et al., 2017)	4DNFIC21MG3U
Human hESC hic	(Oksuz et al., 2020)	4DNFI7JNCNFB
Human IMR90 hic	45	4DNFIJTOIGOI
Human olfactory sensory neurons hic	(Zazhytska et al., 2021)	4DNFI7V61PXA
Human HCT116 hic	42	4DNFIV3PIEQJ
Human K562 hic	(Ray et al., 2019)	4DNFI244AS29
Human HFF hic	(Oksuz et al., 2020)	4DNFIWMLVHWX
Experimental models: Cell lines		
NIH 3T3	ATCC	Cat# CRL-1658 RRID:CVCL 0594

REAGENT or RESOURCE	SOURCE	IDENTIFIER
HEK293T	ATCC	Cat# CRL-3216 RRID:CVCL_0063
Scid.adh	Warren Pear lab at UPENN	
Experimental models: Organisms and Strains		
Mouse: C57BL/6J	Jackson Laboratory	RRID:IMSR_JAX:000664
Mouse: B6(Cg)-Tcf7tm1Hhx/J	Jackson Laboratory	RRID:IMSR_JAX:030909
Mouse: B6.Cg-Commd10Tg(Vav1-icre)A2Kio/J	Jackson Laboratory	RRID:IMSR_JAX:008610
Software and algorithms		
FastQC		https:// www.bioinformatics.babraham.ac.uk/ projects/fastqc/; RRID:SCR_014583
Trim Galore		https:// www.bioinformatics.babraham.ac.uk/ projects/trim_galore/; RRID:SCR_011847
Bowtie2	50	http://bowtie-bio.sourceforge.net/ bowtie2/index.shtml
STAR	51	https://github.com/alexdobin/STAR
Picard		https://broadinstitute.github.io/picard/
HTSeq	52	https://htseq.readthedocs.io/en/ master/; RRID:SCR_005514
DESeq2	53	https://github.com/Bioconductor- mirror/DESeq2; RRID:SCR_015687
R		https://cran.r-project.org; RRID:SCR_001905
MACS2	54	https://github.com/taoliu/MACS
Homer	55	http://homer.ucsd.edu/homer; RRID:SCR_010881
bedtools		https://bedtools.readthedocs.io/en/ latest/#; RRID:SCR_006646
wigToBigWig		http://hgdownload.cse.ucsc.edu/ admin/exe/
HiC-Pro	56	https://github.com/nservant/HiC-Pro; RRID:SCR_017643
ggplot2		https://ggplot2.tidvverse.org/
Metascape	57	https://metascape.org/gp/index.html#/ main/step1; RRID:SCR_016620
Juicer	58	https://github.com/aidenlab/juicer
Cooler		https://github.com/open2c/cooler
cooltools		https://github.com/open2c/cooltools
HiCExplorer	59	https://hicexplorer.readthedocs.io/en/ latest/
UpSetR	60	https://cran.r-project.org/web/ packages/UpSetR/index.html
deeptools	61	https://deeptools.readthedocs.io/en/ develop/
dekker-cworld		https://github.com/dekkerlab/cworld- dekker

REAGENT or RESOURCE	SOURCE	IDENTIFIER
hichipper	62	https://github.com/aryeelab/hichipper
Coolpup.py	63	https://github.com/open2c/coolpuppy
TANGO		
Fiji		
IMARIS		
Sushi		
OligoMiner		
Flowjo v.10.6.1		